ES2368918T3 - NEW DERIVATIVES OF OXAZOLIDINONA. - Google Patents

Abstract

An oxazolidinone derivative of formula I or a pharmaceutically acceptable salt thereof: wherein formula (I) R 1 and R '1 are independently hydrogen or fluorine; R 2 is -OR 7, fluorine, alkyl phosphate, monophosphate or a metal phosphate salt; R 7 is hydrogen, C 1-3 alkyl or acylated amino acid, wherein the amino acid is alanine, proline, isoleucine, leucine, phenylalanine, β-alanine or valine; R 3 is hydrogen, a C 1-4 alkyl group that is unsubstituted or substituted with cyano or - (CH 2) m-OR 7; and m is 0, 1, 2, 3 or 4.

Description

New oxazolidinone derivatives

Technical field

The present invention relates to new oxazolidinone derivatives, methods of preparation thereof and 5 pharmaceutical compositions comprising the same for use in an antibiotic.

Background Technique

Used as orally administrable antibacterial agents, oxazolidinone compounds are not fermentation products, but artificially synthesized ones, and various structures of their derivatives are known. For example, derivatives of 3-phenyl-2-oxazolidinone with one or two substituents are indicated in US Pat. nºs

10 4,948,801, 4,461,773, 4,340,606, 4,476,136, 4,250,318 and 4,128,654. Derivatives of 3- [phenyl (monosubstituted)] - 2oxazolidinone of formula 2 are described in EP 0312000, J. Med. Chem. 32, 1673 (1989), J. Med. Chem. 33, 2569 (1990), Tetrahedron , 45, 123 (1989), etc.

<Formula 2>

15 Pharmacia &amp; Upjohn developed oxazolidinone derivatives of formulas 3 and 4 (WO 93/23384, WO 95/14684 and WO 95/07271). Having obtained success in obtaining approval from the US Food and Drug Administration (FDA), the oxazolidinone derivative of formula 3, with the name "Zyvox", has entered the market. However, it was found that these conventional synthetic oxazolidinone compounds suffer from the disadvantage of showing antibacterial activity against a narrow spectrum of bacteria, being toxic to

20 human beings and being deficient in therapeutic activity in vivo. Zyvox can be used restrictively as an injection, since the solubility of Zyvox against water is inadequate for injection use, which is approximately 3 mg / ml

<Formula 3>

25 <Formula 4>

In addition, WO 93/09103 describes phenyl-oxazolidinone derivatives, substituted with heterocycles such as thiazole, indole, oxazole and quinol, as well as pyridine at position 4 of the phenyl ring. However, it is known that these oxazolidinone derivatives provide insufficient medicinal effects, because the heterocycles

5 carry simple substituents such as alkyl or amino groups.

WO 01/94342 described synthetic derivatives of phenyl-oxazolidinone, with pyridine or phenyl derivatives at position 4 of the phenyl ring. Synthesized compounds are potent in inhibitory activity against a broad spectrum of bacteria and are also antibiotics superior to Zyvox. However, the compounds are unable to be formulated as an injection because their solubility is due to

10 below 30 μg / ml.

European patent application EP 0 352 781 A2 describes derivatives of aminomethyloxy-oxazolidinyl-arylbenzene, wherein the aryl includes the phenyl, substituted phenyl, pyridyl and substituted pyridyl groups such as (I) -N- {3- [4- ( 4- (4-Pyridyl) phenyl] -2-oxo-oxazolidin-5-ylmethyl] acetamide as antibacterial agents.

International patent application WO 03/022824 A1 describes compounds of the following formula (I) or a salt

Pharmaceutically acceptable, or an in vivo hydrolysable ester thereof, and compounds as shown in formula (I), wherein C is, for example, (D), (E), (F); wherein A and B are independently selected from (i) and (ii); R2a to R3b are independently selected from hydrogen and fluorine; R1a and R1b are independently selected, for example, from hydroxy, -NHC (= W) R4, (a) and (b); where W is O or S; R4 is, for example, hydrogen, amino, (C1-4) alkyl; HET-1 is, for example, a 5-membered C-linked heteroaryl ring; Het-2

20 is, for example, a 5-membered heterocyclic ring, linked to N, totally or partially unsaturated, as antibacterial agents.

International patent application WO 2004/048350 A2 describes a compound of the following formula (I) or a

Pharmaceutically acceptable salt, or an in vivo hydrolysable ester thereof, wherein C is selected from (D) and (E), R2a, R6a and R3a are independently selected, for example, from H, CF3, Me and Et; R2b and R6b are independently selected, for example, from H, F, CF3, Me and Et; R1b is, for example, optionally substituted diazolyl, triazolyl or tetrazolyl; R4 is, for example, a 5 or 6 membered heterocyclic ring system as an antibacterial agent.

International patent application WO 2005/005398 A2 describes oxazolidinones with a cyclopropyl moiety, which are effective against aerobic and anaerobic pathogens such as staphylococci, streptococci and multi-resistant enterococci, species of Bacteroides spp, Clostridia spp, as well as organisms resistant to acids such as Mycobacterium tuberculosis and other mycobacterial species. The compounds are represented by the following structural formula (I), their enantiomer, diastereoisomer or pharmaceutically acceptable salt or ester thereof.

Therefore, the intense and thorough search for oxazolidinone derivatives, carried out by the authors of the

The present invention with the aim of overcoming the above problems encountered in the prior art, resulted in the finding of oxazolidinone derivatives as well as prodrugs thereof, wherein the prodrugs are prepared by reacting an amino acid or phosphate with oxazolidinone derivatives that have a hydroxyl group. In addition, salts of oxazolidinone derivatives in the form of prodrugs were readily synthesized using the amino group of the amino acid thereof to synthesize an organic acid or inorganic acid and

15 using a hydroxyl phosphate group and one selected from sodium and calcium. Oxazolidinone derivatives have excellent effects on antibiotic activity and their solubility is strongly enhanced.

Description of the invention

Technical problem

It is an object of the present invention to provide new oxazolidinone derivatives.

It is another object of the present invention to provide a method for preparing the aforementioned derivatives.

It is still another object of the present invention to provide a pharmaceutical composition comprising the aforementioned derivatives for use in an antibiotic.

Technical solution

The present invention provides new oxazolidinone derivatives corresponding to formula I as defined in claim 1.

The oxazolidinone derivatives corresponding to formula I can be used for a pharmaceutically acceptable salt, an acid addition salt prepared using a pharmaceutically acceptable free acid is preferred. The free acid can be inorganic or organic. The inorganic free acid may comprise hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, etc. Organic free acid may include citric acid, acetic acid, lactic acid, maleic acid, fumaric acid, gluconic acid, methanesulfonic acid, glyconic acid, succinic acid, 4-toluenesulfonic acid, trifluoroacetic acid, galacturonic acid, embonic acid, glutamic acid acid

aspartic, etc. Preferred compounds of oxazolidinone derivatives according to the present invention include the following compounds and their structures are described in Table 1. Compounds labeled with an asterisk are for reference and / or comparison only.

1) (S) -3- (4- (2- (2-Oxo-4-glycyloxymethylpyrrolidin-1-yl) pyridin-5-yl) -3-fluorophenyl) -2-oxo-5-oxazolidinylmethyl-acetamide of the acid trifluoroacetic acid, * 2) (S) -3- (4- (2- (4-Glyloxymethylpyrrolidin-1,2,3-triazol-1-yl) pyridin-5-yl) -3-fluorophenyl) -2-oxo- 5-oxazolidinylmethyl acetamide

of trifluoroacetic acid, *

3) (S) -3- (4- (2- (5-Glyloxymethylisoxazol-3-yl) pyridin-5-yl) -3-fluorophenyl) -2-oxo-5-oxazolidinylmethyl-acetamide of trifluoroacetic acid, * 4 ) (R) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5 - ([1,2,4] triazol-1-yl) methyl-oxazolidin-2-one, * 5) (S) -3- (4- (2- (2-oxo-3-glycyloxypyrrolidin-1-yl) pyridin-5-yl) -3-fluorophenyl) -2- acid oxo-5-oxazolidinylmethyl-acetamide

trifluoroacetic, *

6) (S) -3- (4- (2- (5-Glyloxymethyl- [1,2,4] oxadiazol-3-yl) pyridin-5-yl) -3-fluorophenyl) -2-oxo-5- trifluoroacetic acid oxazolidinylmethyl-acetamide, * 7) (S) -3- (4- (2- (5-glycyloxymethyl-1,4,5-dihydroisoxazol-3-yl) pyridin-5-yl) -3-fluorophenyl) -2-oxo-5-oxazolidinylmethyl-acetamide

of trifluoroacetic acid, * 8) (R) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5 - ([1,2,3] triazol-2-yl) methyl-oxazolidin-2-one, * 9) (R) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) - 5 - ([1,2,3] triazol-1-yl) methyl-oxazolidin-2-one, * 10) (R) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin- 5-yl) -3-fluorophenyl) -5-hydroxymethyl-oxazolidin-2-one, * 11) (S) -3- (4- (4- (4,5-dimethyloxazol-2-yl) phenyl) -3 -fluorophenyl) -2-oxo-5-oxazolidinylmethyl-acetamide, * 12) (R) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) - 5-Glyloxymethyl-oxazolidin-2-one-trifluoroacetic acid, * 13) (R) -3- (4- (2- (2-methyl- [1,3,4] oxadiazol-5-yl) pyridin-5- il) -3-fluorophenyl) -5 - ([1,2,3] triazol-1-yl) methyl-oxazolidin-2-one, * 14) (R) -3- (4- (2 - ([1 , 2,4] triazol-1-yl) pyridin-5-yl) -3-fluorophenyl) -5 - ([1,2,3] triazol-1-yl) methyl-oxazolidin-2-one, * 15) (S) -3- (4- (2- (4,5-dimethyloxazol-2-yl) pyridin-5-yl) -3-fluorophenyl) -2-oxo-5-oxazolidinyl) methyl-acetamide, * 16) (R) -3- (4- (2- (2-methyl- [1,3,4] oxadiazol-5-yl) pyridin-5- il) -3-fluorophenyl) -5-hydroxymethyl-oxazolidin-2-one, * 17) (R) -3- (4- (2 - ([1,2,4] triazol-1-yl) pyridin-5 -yl) -3-fluorophenyl) -5-hydroxymethyl-oxazolidin-2-one, * 18) (R) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) - 3-fluorophenyl) -5-fluoromethyl-oxazolidin-2-one, 19) (S) -3- (4- (2- (imidazol-1-yl) pyridin-5-yl) -3-fluorophenyl) hydrochloride - 5-aminomethyl-oxazolidin-2-one, * 20) (R) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- (L -valyloxy) methyl-oxazolidin-2-one-trifluoroacetic acid, 21) (R) -3- (4- (4- (4,5-dimethyloxazol-2-yl) phenyl) -3-fluorophenyl) -5-hydroxymethyl -oxazolidin-2-one, * 22) (R) -3- (4- (2 - ([1,2,3] triazol-1-yl) pyridin-5-yl) -3-fluorophenyl) -5- glycyloxymethyl-oxazolidin-2-one-trifluoroacetic acid, * 23) (R) -3- (4- (4- (4,5-dimethyloxazol-2-yl) phenyl) -3-fluorophenyl) -5-glycyloxymethyl-oxazolidin -2-one-trifluoroacetic acid, * 24) (R) -3- (4- (2 - ([1,2,3] triazol-1-yl) pyridin-5-yl) -3-fluorophenyl) -5 -hydroxymethyl-oxazolidin-2-one, * 25) (S) -3- (4- (2 - ([1,2,3] triazol-2-yl) pyridin-5-yl) -3-fluo rofenil) -2-oxo-5-oxazolidinylmethyl-acetamide, * 26) (S) -3- (4- (4- (4 (S) -hydroxymethyl-4,5-dihydroxazol-2-yl) phenyl) -3 -fluorophenyl) -2-oxo-5-oxazolidinylmethyl-acetamide, * 27) (R) -3- (4- (2- (2-methyl- [1,3,4] oxadiazol-5-yl) pyridin-5 -yl) -3-fluorophenyl) -5-glycyloxymethyl-oxazolidin-2-one-acid

trifluoroacetic, * 28) (S) -3- (4- (4- (4-hydroxymethylthiazol-2-yl) phenyl) -3-fluorophenyl) -2-oxo-5-oxazolidinylmethyl-acetamide, * 29) (R) -3- (4- (2 - ([1,2,3] triazol-2-yl) pyridin-5-yl) -3-fluorophenyl) -5-hydroxymethyl-oxazolidin-2-one, * 30) (R) -3- (4- (4- (4-Glyloxymethylthiazol-2-yl) phenyl) -3-fluorophenyl) -2-oxo-5-oxazolidinylmethyl-acetamide

trifluoroacetic, * 31) (S) -3- (4- (4- (4-Cyanomethylthiazol-2-yl) phenyl) -3-fluorophenyl) -2-oxo-5-oxazolidinylmethyl-acetamide, * 32) (R) -3- (4- (4- (4-Cyanomethylthiazol-2-yl) phenyl) -3-fluorophenyl) -5-hydroxymethyl-oxazolidin-2-one, * 33) (R) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5-methoxymethyl-oxazolidin-2-one, * 34) (R) -3- (4- (4- (4-Cyanomethylthiazol-2-yl) phenyl) -3-fluorophenyl) -5-glycyloxymethyl-oxazolidin-2-one-trifluoroacetic acid, * 35) (R) -3- (4- (2 - ([1,2,3] triazol-2-yl) pyridin-5-yl) -3-fluorophenyl) -5-glycyloxymethyl-oxazolidin-2-one- trifluoroacetic acid, * 36) (R) -3- (4- (4- (4-hydroxymethylthiazol-2-yl) phenyl) -3-fluorophenyl) -5 - ([1,2,3] triazol-1-yl) methyl-oxazolidin -2-one, * 37) (R) -3- (4- (4- (4-Glyloxymethylthiazol-2-yl) phenyl) -3-fluorophenyl) -5 - ([1,2,3] triazol-1-yl) methyl-oxazolidin -2-one-acid

trifluoroacetic, * 38) (R) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3,5-difluorophenyl) -5-hydroxymethyl-oxazolidin-2-one, * 39) (R) -3- (4- (2- (2-methyl- [1,3,4] oxadiazol-5-yl) pyridin-5-yl) -3,5-difluorophenyl) -5-hydroxymethyl- oxazolidin-2-one, * 40) (R) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- (N, N-dimethylaminomethyl) -oxazolidin-2-one , * 41) (R) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- (N-methylaminomethyl) -oxazolidin-2-one, * 42) (R) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- (L-alanyloxy) methyl-oxazolidin-2-one- trifluoroacetic acid, 43) (R) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- (L-valyloxy) methyl-oxazolidin-2- hydrochloride ona, 44) (R) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- (L-alanyloxy) methyl-oxazolidin-2- hydrochloride ona, 45) (R) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5-glycyloxymethyl-oxazolidin-2-one hydrochloride, 46) (R) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- (L-prolynyloxy) methyl-oxazolidin-2-one- acid

trifluoroacetic acid, 47) (R) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- (L-prolynyloxy) methyl-oxazolidin-2- hydrochloride ona, 48) (R) -3- (4- (2- (2-methyl- [1,3,4] oxadiazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5-glycyloxymethyl- hydrochloride oxazolidin-2-one, * 49) (R) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- (β-alanyloxy) methyl-oxazolidin-2-one- trifluoroacetic acid, 50) (R) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- (β-alanyloxy) methyl-oxazolidin-2- hydrochloride ona, 51) (R) -3- (4- (2- (2-methyl- [1,3,4] oxadiazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- (L-alanyloxy ) methyl-oxazolidin-2-one-acid

trifluoroacetic, *

52) (R) -3- (4- (2- (2-methyl- [1,3,4] oxadiazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- (L) hydrochloride -alanyloxy) methyl-oxazolidin-2one, * 53) (R) -3- (4- (2- (2-methyl- [1,3,4] oxadiazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- (L-Valyloxy ) methyl-oxazolidin-2-one-acid

trifluoroacetic, *

54) (R) -3- (4- (2- (2-methyl- [1,3,4] oxadiazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- (L) hydrochloride -valyloxy) methyl-oxazolidin-2one, * 55) (R) -3- (4- (2- (2-methyl- [1,3,4] oxadiazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- (L-prolynyloxy ) methyl-oxazolidin-2-one-acid

trifluoroacetic, *

56) (R) -3- (4- (2- (2-methyl- [1,3,4] oxadiazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- (L) hydrochloride -prolinyloxy) methyl-oxazolidin-2

one, * 57) (R) -3- (4- (2- (2-methyl- [1,3,4] oxadiazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- ( β-alanyloxy) methyl-oxazolidin-2-one-trifluoroacetic acid, *

5 58) (R) -3- (4- (2- (2-methyl- [1,3,4] oxadiazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- ( β-alanyloxy) methyl-oxazolidin-2one, * 59) disodium phosphate of (R) - [3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) - 2-oxo-5-oxazolidinyl] methyl, 60) disodium phosphate of (R) - [3- (4- (2- (2-methyl- [1,3,4] oxadiazol-5-yl) pyridin-5- il) -3-fluorophenyl) -2-oxo-5-oxazolidinyl] methyl, * 61) (R) - [3- (4- (2- (1-methyltetrazol-5-yl) pyridin-5-yl) - 3-fluorophenyl) -5-hydroxymethyl-oxazolidin-2-one, 10 62) (R) - [3- (4- (2- (1-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl ) -5-Glyloxymethyl-oxazolidin-2-one-trifluoroacetic acid, 63) (R) -3- (4- (2- (1-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl hydrochloride ) -5-glycyloxymethyl-oxazolidin-2-one, 64) (R) -3- (4- (2- (1-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- ( L-Alanyloxy) methyl-oxazolidin-2-one-trifluoroacetic acid, 65) (R) -3- (4- (2- (1-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl hydrochloride ) -5- (L-alanyloxy) methyl-oxazolidin-2-one, 66) (R) -3- (4- (2 - (1-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- (L-valyloxy) methyl-oxazolidin-2-one-trifluoroacetic acid, 15 67) (R) -3 hydrochloride - (4- (2- (1-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- (L-valyloxy) methyl-oxazolidin-2-one, 68) (R) -3 - (4- (2- (1-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- (β-alanyloxy) methyl-oxazolidin-2-one-trifluoroacetic acid, 69) hydrochloride (R) -3- (4- (2- (1-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- (β-alanyloxy) methyl-oxazolidin-2-one, 70) (R) - [3- (4- (2- (1-Methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -2-oxo-5-oxazolidinyl] methyl phosphate, 71) ( R) - [3- (4- (2- (1-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5 - ([1,2,3] triazol-1-yl) methyl -oxazolidin-2-one, * 20 72) mono phosphate - [(R) - [3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) - 2-oxo-5-oxazolidinyl] methyl], and 73) mono - [(R) - [3- (4- (2- (1-methyltetrazol-5-yl) pyridin-5-yl) -3- phosphate fluorophenyl) -2-oxo-5-oxazolidinyl] methyl].

A method for preparing oxazolidinone derivatives corresponding to formula I, and similar compounds, is shown in Scheme 1 as defined below.

In Scheme 1, Z represents a C1-4 alkyl group, X, R1, R1 ', R2, R3 and R4 are as defined in formula I and Y represents halogen.

The method for preparing oxazolidinone derivatives comprises replacing a halogen atom with a hydrogen atom in the phenyl of a hydroxymethyloxazolidinone derivative (II), to thereby form a derivative (III) (Step 1);

substitute stanyl for a halogen atom (Y) of the derivative (III) to form a derivative (IV) (Step 2);

reacting the derivative (IV) with pyridine or a phenyl derivative that is substituted with bromine or iodine to form an oxazolidinone derivative (V) having a pyridine ring or a phenyl ring (Step 3); Y

react the derivative (V) with an amino acid having a protective group and then with an acid, to thereby remove the protective group and to form salts of the compounds corresponding to Formula 1, or subject the derivative (V) to which react with phosphate and then with a metal salt, to thereby form salts of the compounds corresponding to Formula 1 (Step 4).

In Step 1, the hydroxymethyloxazolidinone derivative (II) can be synthesized by conventional methods. For example, a method may comprise replacing an amino group of aniline with a benzyloxycarbonyl group, and reacting a substituted compound with glycidyl butylate in a strong base state, to thereby form derivative (II). The state can be prepared by adding a strong base; preferably, the strong base may include n-butyllithium, sec-butyllithium, tert-butyllithium, etc., more preferably n-butyllithium. In addition, it is preferable to subject the method to a temperature of about -78 ° C in liquid nitrogen.

Step 1 is performed to replace a hydrogen atom of the phenyl group of derivative (II) with a halogen atom, preferably an iodine atom. When the hydrogen atom is replaced by the iodine atom, the substituted reaction may preferably be subjected to adding iodine monochloride (ICI) or silver salt of trifluoroacetic acid (CF3COOAg) and adding iodine at room temperature.

Stage 2 consists of reacting the derivative (III) with hexamethyldisten, hexabutyltin or tributyltin hydride by adding a palladium catalyst to form derivative (IV), whose iodine atom is substituted with a trimethylstannyl group or a tributilestannyl group . The palladium catalyst may comprise dichlorobistriphenylphosphine-palladium (II), tetrakistriphenylphosphine-palladium (0), etc. It is preferred to carry out Step 2 in a solvent of 1,4-dioxane, dimethylformamide, tetrahydrofuran, 1-methyl-2-pyrrolidone, etc. at a temperature of about 90 to 150 ° C.

Step 3 is carried out by reacting the derivative (IV) with a compound having a hetero ring in the phenyl or pyridine ring, to thereby form the derivative (V). A palladium catalyst added in Step 3 may be identical to that of palladium in Step 2. It is preferred to carry out Step 3 in a solvent of dimethylformamide, 1-methyl-2-pyrrolidone, etc., at a temperature of about 100 to 120 ° C.

Step 4 is carried out by reacting the derivative (V) with an amino acid that protects an amino group with t-butyloxycarbonyl, dicyclohexylcarbodiimide and 4-dimethylaminopyridine, to thereby form the derivative (I) having an amino group. The amino acid may include alanine, glycine, proline, isoleucine, leucine, phenylalanine, -alanine,

β valine, etc. A solvent comprises dimethylformamide, 1-methyl-2-pyrrolidone, etc. Preferably, a reaction is carried out by adding the derivative (V) with amino acid while stirring for about 5 hours above room temperature.

A mixture of the derivative (V) and the amino acid reacts to form a strong acid such as trifluoroacetic acid, etc., to remove a protective group. The solvent is separated from the mixture, and the mixture is crystallized, to thereby provide a salt of the oxazolidinone derivative corresponding to Formula 1. Preferably, a reaction is carried out by adding the derivative (V) with an amino acid upon stirring. for about 2 hours above room temperature.

The salt of the derivative of Formula 1, prepared by using the amino acid in the R3 or R4 position in a known method, can be obtained in a manner similar to the previous method. (S) -3- (4-Trimethylstannyl-3-fluorophenyl) -2-oxo-5oxazolidinylmethyl-acetamide is known as a starting material in the method, and the method is described in WO 0194342.

In addition, a phosphate metal salt of derivative (I) can be formed by adding sodium methoxide, sodium hydroxide, etc. To a composition in a solvent such as methanol, ethanol, etc., the composition is prepared by dissolving derivative (V) in trimethyl phosphate or triethyl phosphate, adding phosphorous oxychloride and stirring for approximately 12 hours at room temperature. The metal phosphate salt can be produced by reacting the derivative (V) with tetrazole and amidite derivatives at room temperature, oxidizing a compound that has reacted, synthesizing an alkyl phosphate derivative, removing the alkyl group using a strong acid to thereby forming a phosphate acid derivative and converting the phosphate acid derivative into the metal phosphate salt by the method mentioned above.

In addition, the present invention provides a pharmaceutical composition comprising the oxazolidinone derivatives corresponding to Formula 1 for use in an antibiotic.

The oxazolidinone derivatives of the present invention show an inhibitory activity against a broad spectrum of bacteria, against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) and have excellent activity. relatively antibiotic with a relatively low concentration thereof or in vivo.

In addition, derivatives of the present invention can exert potent antibacterial activity against various human and animal pathogens, including Gram-positive bacteria such as staphylococci, enterococci and streptococci, anaerobic microorganisms such as Bacteroides and Clostridia, and acid resistant microorganisms such like Mycobacterium tuberculosis and Mycobacterium avium.

The oxazolidinone derivatives with hydroxyl are reacted with amino acid or phosphate to form prodrugs thereof. Prodrugs have superior solubility with respect to compounds that are not formed as prodrugs: the solubility of the prodrugs represents a value above 28 mg / ml, and the solubility of compound one is 10 mg / ml (compound 10). The prodrugs are stabilized in water or in an acidic solution and change to hydroxymethyl compounds when inverted when using stearase and phosphatase in the blood, to thereby develop a simple formulation for injection or oral administration.

The composition of the present invention may comprise at least one effective ingredient having functions similar to those of oxazolidinone derivatives.

To formulate a pharmaceutical composition, at least one species of the compound of Formula 1 may be mixed with at least one pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier may include saline solution, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol, etc. According to the needs of the user, the pharmaceutical composition may contain a conventional excipient such as antioxidant agent, buffer, soil cleaning agent, etc. Also, the compositions are mixed with diluents, disintegrants, surfactants, binders, lubricants, aqueous solution, suspension, etc. to be formed for injection, powders, capsules, granules, tablets, etc. Preferably, the formulation is prepared using suitable methods described in Remington’s Pharmaceutical Science (the most recent edition), Mack Publishing Company, Easton PA, etc. according to the diseases or ingredients.

The compound of the present invention can be administered orally or parenterally, such as intravenously, hypodermally, intra-abdominally, topically, etc. The dosage of the compound may vary depending on the particular compound used, the mode of administration, the state and severity thereof, the condition being treated as well as the various physical factors related to the individual being treated. As used in accordance with the invention, satisfactory results can be obtained when the compounds of the present invention are administered to the individual in need at a daily dosage of about 10 mg to about 25 mg per kilogram of body weight, preferably approximately 13 mg to approximately 20 mg per kilogram of body weight, more preferably each is administered in divided doses for many times a day.

The lethal dose (LD50) of oxazolidinone derivatives is manifested above 1 g / kg in the acute toxicity test, so that the derivatives are found to be stable.

Advantageous effects

The oxazolidinone derivatives of the present invention show an inhibitory activity against a broad spectrum of bacteria and a low toxicity. Prodrugs, prepared by reacting the hydroxyl compound with amino acid or phosphate have a high solubility against water.

In addition, derivatives of the present invention can exert potent antibacterial activity against various human and animal pathogens, including Gram-positive bacteria such as staphylococci, enterococci and streptococci, anaerobic microorganisms such as Bacteroides and Clostridia and acid resistant microorganisms such as Mycobacterium tuberculosis and Mycobacterium avium.

Accordingly, compositions comprising oxazolidinone derivatives are used in an antibiotic.

Best way to carry out the invention

The examples are given for the purpose of illustration only and are not considered limitations of the present invention, since many variations thereof are possible without departing from the spirit and scope of the invention.

Preparation Example 1: Preparation of N-carbobenzyloxy-3-fluoroaniline

3-Fluoroaniline, 100 g, was dissolved in 1 L of tetrahydrofuran (THF) and 150 g (1.8 mol) of sodium bicarbonate (NaHCO3) was added to the solution. After being cooled to 0 ° C, 154 ml of N-carbobenzyloxy chloride (CbzCl) was slowly added to the solution for the reaction. While the temperature was maintained at 0 ° C, the reaction mixture was allowed to react for 2 hours with stirring. After that, the reaction was extracted with 0.5 L of ethyl acetate. The organic layer, after being separated, was washed with brine, dried over anhydrous magnesium sulfate (MgSO4) and concentrated in vacuo. The residue was washed twice with n-hexane to provide the title compound as a white crystal. 132 g 85% yield.

Preparation Example 2: Preparation of (R) -3- (3-fluorophenyl) -2-oxo-5-oxazolidinylmethanol

132 g of N-carbenzyloxy-3-fluoroaniline, prepared in Preparation Example 1, were dissolved in 1.3 L of tetrahydrofuran, and the solution was cooled to -78 ° C. To the solution 370 ml of n-butyllithium (n-BuLi, 1.6 M / n-hexane) was slowly added under a nitrogen atmosphere, followed by stirring for 10 min. And 84 ml of (R) - (-) - glycidyl butylate was slowly added to the reaction mixture, stirred at the same temperature for 2 hours and allowed to react for 24 hours at room temperature. After completion of the reaction, ammonium chloride solution (NH4Cl) was added to the solution and extracted with 0.5 L of ethyl acetate at room temperature. The organic layer, thus separated, was washed with brine, dried over anhydrous magnesium sulfate and concentrated in vacuo. The residue was dissolved in 100 ml of ethyl acetate and washed with n-hexane to give white crystals that were purified to give the title compound. 80 g 70% yield.

1H NMR (DMSO-d6) δ 7.85 (t, 1H), 7.58 (dd, 1H), 7.23 (dd, 1H), 4.69 (m, 1H), 4.02 (t, 1H), 3.80 (dd, 1H), 3.60 (wide dd, 2H).

Preparation Example 3: Preparation of (R) -3- (4-iodo-3-fluorophenyl) -2-oxo-5-oxazolidinylmethanol

In 300 ml of acetonitrile, 30 g of (R) -3- (3-fluorophenyl) -2-oxo-5-oxazolidinylmethanol prepared in Preparation Example 2 were dissolved, and 46 g of silver salt of the acid were added to the solution trifluoroacetic acid (CF3COOAg) and 43 g of iodide. After stirring for one day at room temperature, water was added to the solution and extracted with ethyl acetate. The organic layer, thus separated, was washed with brine, and dehydrated. And then, the residue was filtered, concentrated in vacuo and dried to thereby form the title compound. 44 g 94% yield.

1 H NMR (DMSO-d6) δ 7.77 (t, 1 H), 7.56 (dd, 1 H), 7.20 (dd, 1 H), 5.20 (m, 1 H), 4.70 (m, 1H), 4.07 (t, 1H), 3.80 (m, 1H), 3.67 (m, 2H), 3.56 (m, 3H).

Preparation Example 4: Preparation of (R) -3- (4-tributylstannyl-3-fluorophenyl) -2-oxo-5-oxazolidinylmethanol

In 660 ml of 1,4-dioxane 50 g of (R) -3- (4-iodo-3-fluorophenyl) -2-oxo-5-oxazolidinylmethanol prepared in Preparation Example 3 were dissolved, to the solution were added 52 g of hexabutyldistane ((Bu3Sn) 2) and 9.3 g of dichlorobistriphenylphosphine-palladium, and stirred for 2 hours. The solution was filtered using celite and concentrated in vacuo. The residue was purified by column chromatography and 45 g of the title compound formed.

1H NMR (DMSO-d6) δ 7.74 (m, 3H), 5.20 (t, 1H), 4.71 (m, 1H), 4.08 (t, 1H), 3.82 (dd, 1H), 3.68 (m, 1H), 3.52 (m, 1H), 1.48 (m, 6H), 1.24 (m, 6H), 1.06 (m, 6H), 0, 83 (t, 9H).

Preparation Example 5: Preparation of 2-cyano-5-bromopyridine

100 g of 2,5-dibromopyridine was dissolved in 1 L of dimethylformamide, 32 g of copper cyanide and 17.8 g of sodium cyanide were added to the solution at room temperature, and the solution was stirred at the temperature of 150 ° C for 7 hours for the reaction. After being cooled to room temperature, water was added to the reaction mixture and extracted with ethyl acetate. The organic layer was washed with brine, dehydrated, filtered and concentrated in vacuo. The title compound, 54 g, was obtained. 70% yield.

1 H NMR (CDCl 3) δ 8.76 (s, 1 H), 7.98 (dd, 1 H), 7.58 (dd, 1 H)

Preparation Example 6: Preparation of 2- (tetrazol-5-yl) -5-bromopyridine

10 g of 2-cyano-5-bromopyridine, prepared in Preparation Example 5, were dissolved in 100 ml of dimethylformide, 5.33 g of sodium azide and 4.4 g of ammonium chloride were added to the solution at room temperature, and the solution was stirred at a temperature of 110 ° C for 3 hours for the reaction. Water was added to the reaction mixture and then extracted with ethyl acetate. The organic layer, thus separated, was washed with brine, dehydrated, filtered and concentrated in vacuo, to thereby obtain 10.5 g of the title compound. 85% yield.

Preparation Example 7: Preparation of 2- (1-methyltetrazol-5-yl) -5-bromopyridine and 2- (2-methyltetrazol-5-yl) -5bromopyridine

10.5 g of 2- (tetrazol-5-yl) -5-bromopyridine, prepared in Preparation Example 6, was dissolved in 100 ml of dimethylformamide. And then 6.5 g of sodium hydroxide were added to the solution, and 9.3 g of iodomethane were added slowly to the solution at a temperature of 0 ° C. The solution was stirred for 6 hours at room temperature, water was added and extracted with ethyl acetate. And then the organic layer was washed with brine, dehydrated, filtered, concentrated in vacuo and purified by column chromatography to obtain 4 g of 2- (1 methyltetrazol-5-yl) -5-bromopyridine and 5 g of 2- (2 -methyltetrazol-5-yl) -5-bromopyridine.

1) 2- (1-methyltetrazol-5-yl) -5-bromopyridine

1 H NMR (CDCl 3) δ 8.77 (t, 1 H), 8.23 (dd, 1 H), 8.04 (dd, 1 H), 4.46 (s, 3 H)

2) 2- (2-methyltetrazol-5-yl) -5-bromopyridine

1 H NMR (CDCl 3) δ 8.80 (t, 1 H), 8.13 (dd, 1 H), 7.98 (dd, 1 H), 4.42 (s, 3 H)

Preparation Example 8: Preparation of 2- (2-methyl- [1,3,4] oxadiazol-5-yl) -5-bromopyridine

reaction mixture was added ethyl acetate and extracted to separate the organic layer. And then the organic layer was washed with water and brine. The organic layer was dehydrated, filtered and concentrated in vacuo to give 7.3 g of the title compound. 80% yield.

1 H NMR (CDCl 3) δ 7.99 (t, 1 H), 7.40 (dd, 1 H), 7.27 (dd, 1 H), 1.83 (s, 3 H)

Preparation Example 9: Preparation of 2 - ([1,2,3] triazol-1-yl) -5-bromopyridine and 2 - ([1,2,3] triazol-2-yl) -5bromopyridine

20 g of 2,5-dibromopyridine were dissolved in 200 ml of 1-methyl-2-pyrrolidone. To the solution was added 35 g of potassium carbonate and stirred for 10 hours at the temperature of 100 ° C. To the reaction mixture was added ethyl acetate, and the organic layer, thus obtained, was washed with water and brine. The organic layer was dried, filtered and concentrated in vacuo to provide 6 g of 2 - ([1,2,3] triazol-1-yl) -5-bromopyridine and 4 g 2 - ([1,2,3] triazole -2-yl) -5bromopyridine.

1) 2 - ([1,2,3] triazol-1-yl) -5-bromopyridine

1H NMR (CDCl3) δ 8.53 (dd, 2H), 8.10 (d, 1H), 8.03 (dd, 1H), 7.82 (s, 1H)

2) 2 - ([1,2,3] triazol-2-yl) -5-bromopyridine

1 H NMR (CDCl 3) δ 8.60 (t, 1 H), 7.97 (s, 2 H), 7.87 (s, 2 H)

Example 1: Preparation of (R) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5-hydroxymethyl-oxazolidin-2-one (Compound 10)

In 150 ml of 1-methyl-2-pyrrolidone 37 g of (R) -3- (4-tributylstannyl-3-fluorophenyl) -2-oxo-5oxazolidinylmethanol were dissolved. To the solution were added 19.7 g of 2- (2-methyltetrazol-5-yl) -5-bromopyridine, 10.44 g of lithium chloride and 2.9 g of dichlorobistriphenylphosphine-palladium (II) at room temperature and then stirred at a temperature of 120 ° C for 4 hours. Water was added to the reaction mixture and then extracted with ethyl acetate. The organic layer, thus separated, was washed with brine, dehydrated, filtered, concentrated in vacuo and purified by column chromatography to provide 8 g of the title compound. 26% yield.

1 H NMR (DMSO-d6) δ 8.90 (s, 1 H), 8.18 (m, 2 H), 7.70 (m, 2 H), 7.49 (dd, 1 H), 5.25 (t, 1H), 4.74 (m, 1H), 4.46 (s, 3H), 4.14 (t, 1H), 3.88 (dd, 1H), 3.68 (m, 1H), 3, 58 (m, 1 H).

Example 2: Preparation of (R) -3- (4- (2- (2-methyl- [1,3,4] oxadiazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5-hydroxymethyloxazolidin -2-one (Compound 16) *

The title compound 6.6 g (30% yield) was prepared in a method similar to that of Example 1, except that 14.3 g of 2- (2-methyl- [1,3,4] were used as starting material ] oxadiazol-5-yl) -5-bromopyridine instead of 2- (2-methyltetrazol-5-yl) -bromopyridine.

1 H NMR (DMSO-d6) δ 8.93 (s, 1 H), 8.21 (s, 2 H), 7.71 (m, 2 H), 7.50 (dd, 1 H), 5.25 (t, 1H), 4.74 (m, 1H), 4.14 (t, 1H), 3.89 (dd, 1H), 3.68 (m, 1H), 3.59 (m, 1H), 2, 64 (s, 3H).

Example 3: Preparation of (R) -3- (4- (2 - ([1,2,4] triazol-1-yl) pyridin-5-yl) -3-fluorophenyl) -5-hydroxymethyl-oxazolidin-2one (Compound 17) *

The same process as in Example 1 was performed, except that instead of 2- (2-methyltetrazol-5-yl) -5-bromoporidine, 200 mg of 2- ([1,2,4] triazole-) were used. 1-yl) -5-bromopyridine as a starting material to prepare the title compound, 150 mg, yield 48%.

Example 4: Preparation of (R) -3- (4- (4- (4,5-dimethyloxazol-2-yl) phenyl) -3-fluorophenyl) -5-hydroxymethyl-oxazolidin-2one (Compound 21) *

The same process as in Example 1 was performed, except that instead of 2- (2-methyltetrazol-5-yl) -5-bromoporidine, 1 g of 4- (4,5-dimethyloxazol-2-yl) was used ) Bromobenzene as a starting material to prepare the title compound, 780 mg, (yield 76%.).

1H NMR (DMSO-d6) δ 7.96 (s, 1H), 7.94 (s, 1H), 7.63 (m, 4H), 7.44 (dd, 1H), 5.23 (t, 1H), 4.72 (m, 1H), 4.12 (t, 1H), 3.87 (dd, 1H), 3.68 (m, 1H), 3.56 (m, 1H), 2, 32 (s, 3H), 2.10 (s, 3H).

Example 5: Preparation of (R) -3- (4- (2- [1,2,3] triazol-1-yl) pyridin-5-yl) -3-fluorophenyl) -5-hydroxymethyl-oxazolidin-2one ( Compound 24) *

The same process as in Example 1 was performed, except that instead of 2- (2-methyltetrazol-5-yl) -5-bromoporidine, 2 g of 2 - ([1,2,3] triazole-) were used. 1-yl) -5-bromopyridine as a starting material to prepare the title compound, 1.2 g.

1 H NMR (DMSO-d6) δ 8.88 (s, 1 H), 8.76 (s, 1 H), 8.28 (d, 1 H), 8.21 (d, 1 H), 8.01 (s, 1H), 7.70 (m, 2H), 7.51 (dd, 1H), 5.26 (t, 1H), 4.75 (m, 1H), 4.14 (t, 1H), 3, 90 (dd, 1H), 3.68 (m, 1H), 3.58 (m, 1H).

Example 6: Preparation of (R) -3- (4- (2- [1,2,3] triazol-2-yl) pyridin-5-yl) -3-fluorophenyl) -5-hydroxymethyl-oxazolidin-2one ( Compound 29) *

The same process as in Example 1 was performed, except that instead of 2- (2-methyltetrazol-5-yl) -5-bromoporidine, 1 g of 2 - ([1,2,3] triazole-) was used 2-yl) -5-bromopyridine as a starting material to prepare the title compound, 0.7 g.

1H NMR (DMSO-d6) δ 8.74 (s, 1H), 8.25 (dd, 1H), 8.23 (s, 1H), 8.11 (d, 1H), 7.69 (m, 3H), 7.49 (dd, 1H), 5.24 (t, 1H), 4.75 (m, 1H), 4.14 (t, 1H), 3.89 (dd, 1H), 3, 68 (m, 1H), 3.59 (m, 1H).

Example 7: Preparation of (R) -3- (4- (4- (4-cyanomethyl-thiazol-2-yl) phenyl) -3-fluorophenyl) -5-hydroxymethyl-oxazolidin-2one (Compound 32) *

The same process as in Example 1 was performed, except that instead of 2- (2-methyltetrazol-5-yl) -5-bromoporidine, 1 g of 4- (4-cyanomethyl-thiazol-2-yl) was used ) -bromobenzene as a starting material to prepare the title compound, 520 mg.

1 H NMR (DMSO-d6) δ 8.04 (s, 1 H), 8.00 (s, 1 H), 7.65 (m, 5 H), 7.47 (dd, 1 H), 5.24 (t, 1H), 4.74 (m, 1H), 4.23 (s, 2H), 4.13 (t, 1H), 3.88 (dd, 1H), 3.68 (m, 1H), 3, 59 (m, 1 H).

Example 8: Preparation of (R) -3- (4- (2- (2-methyltetrazol-5-yl) pridin-5-yl) -3-fluorophenyl) -3,5-difluorophenyl) -5-hydroxymethyl-oxazolidin-2 -one (Compound 38)

The same process was performed as in Example 1, except that (R) -3- (4-tributyl-stannyl-3) was used instead of (R) -3- (4-tributylstannyl-3-fluorophenyl) -2oxo-oxazolidinylmethanol , 4-difluorophenyl) -2-oxo-5-oxazolidinylmethanol as a starting material to prepare the title compound.

1H NMR (DMSO-d6) δ 8.81 (s, 1H), 8.25 (d, 1H), 8.10 (d, 1H), 7.54 (d, 2H), 5.25 (t, 1H), 4.77 (m, 1H), 4.47 (s, 3H), 4.13 (t, 1H), 3.89 (dd, 1H), 3.68 (m, 1H), 3, 57 (m, 1 H).

Example 9: Preparation of (R) -3- (4- (2- (2-methyl- [1,3,4] oxadiazol-5-yl) pridin-5-yl) -3,4-difluorophenyl) - 5-hydroxymethyl-oxazolidin-2-one (Compound 39) *

The same process was carried out as in Example 1, using (R) -3- (4-tributylstannyl-3,4-difluorophenyl) -2-oxo-5oxazolidinylmethanol and 2- (2-methyl- [1,3,4] oxadiazol-5-yl) -5-bromopyridine as a starting material to prepare the title compound.

1 H NMR (DMSO-d6) δ 8.83 (s, 1 H), 8.25 (d, 1 H), 8.15 (d, 1 H), 7.55 (d, 2 H), 5.25 (t, 1H), 4.77 (m, 1H), 4.13 (t, 1H), 3.89 (dd, 1H), 3.68 (m, 1H), 3.59 (m, 1H), 2, 63 (s, 3H).

Example 10: Preparation of (R) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5-glycyloxymethyloxazolidin-2-one-trifluoroacetic acid (Compound 12)

4 g of (R) -3- (4- (2- (2-methyltetrazol-5-yl) -pyridin-5-yl) -3-fluorophenyl) -5-hydroxymethyl-oxazolidin-2- was dissolved in 25 ml of dimethylformamide one (Compound 10). To the solution were added 3.34 g of 1,3-dicyclohexylcarbodiimide, 2.36 g of BOC-glycine and 0.2 g of 4-dimethylaminopyridine at room temperature and then stirred for 10 hours. Water was added to the reaction mixture and extracted with ethyl acetate. The organic layer, thus separated, was washed with brine, dehydrated, filtered, concentrated in vacuo and purified by column chromatography. A residue, which resulted in concentrating in vacuo, was dissolved in 70 ml of methylene chloride, 30 ml of trifluoroacetic acid was added and stirred for 2 hours at room temperature. The residue was washed with ethanol and ethyl ether and concentrated in vacuo to obtain the title compound, 4.47 g. Yield 76%.

1H NMR (DMSO-d6) δ 8.92 (s, 1H), 8.19 (s, 3H), 8.17 (m, 2H), 7.77 (t, 1H), 7.69 (dd, 1H), 7.49 (dd, 1H), 5.00 (m, 1H), 4.46 (m, 2H), 4.47 (s, 3H), 4.24 (t, 1H), 3, 92 (dd, 1H), 3.90 (s, 2H).

Example 11: Preparation of (R) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- (L-valyloxy) methylxazolidin-2-one -trifluoroacetic acid (Compound 20)

The title compound was prepared in a method similar to that of Example 10, using BOC-valine instead of BOCglycine.

1 H NMR (DMSO-d6) δ 8.92 (s, 1 H), 8.40 (s, 3 H), 8.21 (m, 2 H), 7.76 (t, 1 H), 7.65 (dd, 1H), 7.48 (dd, 1H), 5.05 (m, 1H), 4.63 (dd, 1H), 4.47 (s, 3H), 4.43 (dd, 1H), 4, 28 (t, 1H), 4.01 (d, 1H), 3.93 (dd, 1H), 2.14 (m, 1H), 0.98 (d, 3H), 0.95 (d, 3H ).

Example 12: Preparation of (R) -3- (4- (2- [1,2,3] triazol-1-yl-pyridin-5-yl) -3-fluorophenyl) -5-glycyloxymethyl-oxazolidin2-one- trifluoroacetic acid (Compound 22) *

The title compound was prepared in a method similar to that of Example 10, using Compound 24.

1H NMR (DMSO-d6) δ 8.87 (s, 1H), 8.76 (s, 1H), 8.33 (s, 3H), 8.29 (d, 1H), 8.00 (s, 1H), 7.77 (t, 1H), 7.76 (t, 1H), 7.67 (dd, 1H), 7.47 (dd, 1H), 5.02 (m, 1H), 4, 49 (m, 2H), 4.23 (t, 1H), 3.93 (m, 3H).

Example 13: Preparation of (R) -3- (4- (4- (4,5-dimethyloxazol-2-yl) phenyl) -3-fluorophenyl) -5-glycyloxymethyl-oxazolidin-2ona-trifluoroacetic acid (Compound 23) *

The title compound was prepared in a method similar to that of Example 10, using Compound 21.

1H NMR (DMSO-d6) δ 8.31 (s, 3H), 7.97 (d, 2H), 7.64 (m, 4H), 7.45 (dd, 1H), 5.01 (m, 1H), 4.47 (m, 2H), 4.25 (t, 1H), 3.94 (dd, 1H), 3.90 (s, 2H).

Example 14: Preparation of (R) -3- (4- (2- (2-methyl- [1,3,4] oxadiazol-5-yl) -pyridin-5-yl) -3-fluorophenyl) -5- glycyloxymethyloxazolidin-2-one-trifluoroacetic acid (Compound 27) *

The title compound was prepared in a method similar to that of Example 10, using Compound 16.

1H NMR (DMSO-d6) δ 8.96 (s, 1H), 8.31 (s, 3H), 8.22 (s, 2H), 7.76 (t, 1H), 7.66 (dd, 1H), 7.50 (dd, 1H), 5.04 (m, 1H), 4.50 (m, 2H), 4.25 (t, 1H), 3.94 (dd, 1H), 3, 91 (s, 2H), 2.63 (s, 3H).

Example 15: Preparation of (R) -3- (4- (4- (4-cyanomethyl-thiazol-2-yl) phenyl) -3-fluorophenyl) -5-glycyloxymethyl-oxazolidin-2-one-trifluoroacetic acid (Compound 34) *

The title compound was prepared in a method similar to that of Example 10, using Compound 32.

1H NMR (DMSO-d6) δ 8.25 (s, 3H), 8.03 (d, 2H), 7.68 (m, 5H), 7.44 (dd, 1H), 5.01 (m, 1H), 4.48 (m, 2H), 4.25 (m, 3H), 3.92 (m, 3H).

Example 16: Preparation of (R) -3- (4- (2 - ([1,2,3] triazol-2-yl) -pyridin-5-yl) -3-fluorophenyl) -5-glycyloxymethyl-oxazolidin2- one-trifluoroacetic acid (Compound 35) *

The title compound was prepared in a method similar to that of Example 10, using Compound 29.

1H NMR (DMSO-d6) δ 8.78 (s, 1H), 8.23 (m, 2H), 8.22 (s, 3H), 8.20 (s, 1H), 8.12 (d, 1H), 7.75 (t, 1H), 7.67 (dd, 1H), 7.48 (dd, 1H), 5.01 (m, 1H), 4.49 (m, 2H), 4, 24 (t, 1H), 3.92 (dd, 1H), 3.89 (s, 2H).

Example 17: Preparation of (S) -3- (4- (2- (2-oxo-4-glycyloxymethylpyrrolidin-1-yl) -pyridin-5-yl) -3-fluorophenyl) -2-oxo-5oxazolidinylmethyl-acetamide of trifluoroacetic acid (Compound 1) *

1. The primary stage

In 14 ml of 1-methyl-2-pyrrolidone, 1.8 g of (S) -3- (4-trimethylstannyl-3-fluorophenyl) -2-oxo-oxazolidinylmethylacetamide were dissolved. To the solution were added 1.03 g of 2- (2-oxo-4-hydroxymethylpyrrolidin-1-yl) -5-bromopyridine, 0.55 g of lithium chloride and 0.15 g of dichlorobistriphenylphosphine-palladium (II) at room temperature and then stirred at a temperature of 110 ° C for 2 hours. Water was added to the reaction mixture and extracted with ethyl acetate. After washing with brine, the organic layer thus separated, was dehydrated, filtered, concentrated in vacuo and purified by column chromatography to thereby obtain (S) -3- (4- (2- (2-oxo-4- hydroxymethylpyrrolidin-1-yl) -pyridin-5-yl) -3fluorophenyl) -2-oxo-5-oxazolidinylmethyl-acetamide, 410 mg. Yield 21%.

2. The secondary stage

In dimethylformamide, 2.3 ml, 50 mg of the compound prepared in the primary stage was dissolved. To the solution were added 35 mg of 1,3-dicyclohexylcarbodiimide, 25 mg of BOC-glycine and 2.1 mg of 4-dimethylaminopyridine at room temperature and then stirred for 10 hours. Water was added to the reaction mixture and extracted with ethyl acetate. After washing with brine, the organic layer, thus separated, was dehydrated, filtered, concentrated in vacuo and purified by column chromatography. A residue, provided when concentrated, was dissolved in 2 ml of methylene chloride, 1 ml of trifluoroacetic acid was added and then stirred for 2 hours at room temperature. The residue was washed with ethanol and ethyl ether, and evaporated in vacuo to obtain the title compound, 140 mg.

1 H NMR (DMSO-d6) δ 8.60 (s, 1 H), 8.40 (d, 1 H), 8.28 (s, 3 H), 8.25 (m, 1 H), 8.08 (dd, 1H), 7.63 (m, 2H), 7.42 (dd, 1H), 4.76 (m, 1H), 4.27 (s, 2H), 4.16 (q, 2H), 3, 87 (s, 2H), 3.80 (m, 2H), 3.42 (m, 2H), 2.62 (m, 1H), 2.11 (m, 1H9, 1.83 (s, 3H) .

Example 18: Preparation of (S) -3- (4- (2- (4-glycyloxymethyl- [1,2,3] triazol-1-yl) pyridin-5-yl) -3-fluorophenyl) -2-oxo -5oxazolidinylmethyl-acetamide of trifluoroacetic acid (Compound 2) *

The same process as in Example 17 was performed, except that instead of 2- (2-oxo-4-hydroxymethylpyrrolin-1-yl) -5-bromopyridine, 2- (4-hydroxymethyl- [1,2,3] ] triazol-1-yl) -5-bromopyridine as a starting material to prepare the title compound.

1H NMR (DMSO-d6) δ 8.96 (s, 1H), 8.89 (s, 1H), 8.22 (m, 6H), 7.74 (t, 1H), 7.68 (dd, 1H), 7.48 (dd, 1H), 5.42 (s, 2H), 4.78 (m, 1H), 4.19 (t, 1H), 3.91 (s, 2H), 3, 79 (dd, 1H), 3.43 (m, 2H), 1.83 (s, 3H).

Example 19: Preparation of (S) -3- (4- (2- (5-Glyloxymethylisoxazol-3-yl) pyridin-5-yl) -3-fluorophenyl) -2-oxo-5oxazolidinylmethyl-acetamide of trifluoroacetic acid (Compound 3) *

The same process was performed as in Example 17, except that instead of 2- (2-oxo-4-hydroxymethylpyrrolin-1-yl) -5-bromopyridine, 2- (5-hydroxymethylisoxazole) -5-bromopyridine was used as the material Starting to prepare the title compound.

1H NMR (DMSO-d6) δ 8.89 (s, 1H), 8.26 (s, 3H), 8.12 (m, 2H), 7.72 (t, 1H), 7.64 (dd, 1H), 7.48 (dd, 1H), 7.21 (s, 1H), 5.49 (s, 2H), 4.77 (m, 1H), 4.17 (t, 1H), 3, 98 (s, 2H), 3.79 (m, 1H), 3.43 (m, 2H), 1.83 (s, 3H).

Example 20: Preparation of (S) -3- (4- (2- (2-oxo-3-glycyloxypyrrolidin-1-yl) pyridin-5-yl) -3-fluorophenyl) -2-oxo-5oxazolidinylmethyl-acetamide trifluoroacetic acid (Compound 5) *

The same process was performed as in Example 17, except that instead of 2- (2-oxo-4-hydroxymethylpyrrolin-1-yl) -5-bromopyridine, 2- (2-oxo-3-hydroxypyrrolidine-1-) il) -5-bromopyridine as a starting material to prepare the title compound.

1 H NMR (DMSO-d6) δ 8.60 (s, 1 H), 8.33 (d, 1 H), 8.28 (s, 3 H), 8.25 (m, 1 H), 8.05 (d, 1H), 7.63 (m, 2H), 7.42 (dd, 1H), 5.78 (t, 1H), 4.78 (m, 1H), 4.16 (q, 2H), 3, 98 (s, 2H), 3.85 (m, 1H), 3.78 (m, 1H), 3.43 (m, 2H), 2.62 (m, 1H), 2.12 (m, 1H ), 1.83 (s, 3H).

Example 21: Preparation of (S) -3- (4- (2- (5-glycyloxymethyl- [1,2,4] oxadiazol-3-yl) pyridin-5-yl) -3-fluorophenyl) -2-oxo -5oxazolidinylmethyl-acetamide of trifluoroacetic acid (Compound 6) *

The same process as in Example 17 was performed, except that instead of 2- (2-oxo-4-hydroxymethylpyrrolin-1-yl) -5-bromopyridine, 2- (5-hydroxymethyl [1,2,4]) was used oxadiazol-3-yl) -5-bromopyridine as a starting material to prepare the title compound.

1 H NMR (DMSO-d6) δ 8.95 (s, 1 H), 8.32 (s, 3 H), 8.21 (m, 3 H), 7.75 (t, 1 H), 7.65 (dd, 1H), 7.47 (d, 1H), 5.67 (s, 1H), 4.78 (m, 1H), 4.18 (t, 1H), 4.05 (s, 2H), 3, 80 (m, 1H), 3.43 (m, 2H), 1.83 (s, 3H).

Example 22: Preparation of (S) -3- (4- (2- (5-glycyloxymethyl-4,5-dihydroisoxazol-3-yl) pyridin-5-yl) -3-fluorophenyl) -2oxo-5-oxazolidinylmethyl- trifluoroacetic acid acetamide (Compound 7) *

The same process as in Example 17 was performed, except that instead of 2- (2-oxo-4-hydroxymethylpyrrolin-1-yl) -5-bromopyridine, 2- (5-hydroxymethyl-4,5-dihydroisoxazole) was used 1-yl) -5-bromopyridine as a starting material to prepare the title compound.

1H NMR (DMSO-d6) δ 8.81 (s, 1H), 8.27 (t, 1H), 8.24 (s, 3H), 8.05 (m, 2H), 7.69 (m, 2H), 7.44 (d, 1H), 5.04 (m, 1H), 4.76 (m, 1H), 4.41 (dd, 1H), 4.32 (m, 1H), 4, 17 (t, 1H), 3.86 (s, 2H), 3.77 (m, 1H), 3.60 (m, 1H), 3.44 (m, 2H), 1.83 (s, 3H ).

Example 23: Preparation of (S) -3- (4- (4- (4-Glyloxymethylthiazol-2-yl) phenyl) -3-fluorophenyl) -2-oxo-5-oxazolidinylmethylacetamide of trifluoroacetic acid (Compound 30) *

The same process as in Example 17 was performed, except that instead of 2- (2-oxo-4-hydroxymethylpyrrolin-1-yl) -5-bromopyridine, 4- (4-hydroxymethyl-thiazol-2-yl) was used -bromobenzene as a starting material to prepare the title compound.

1 H NMR (DMSO-d6) δ 8.25 (s, 3H), 8.00 (d, 2H), 7.85 (s, 1H), 7.69 (m, 4H), 7.44 (dd, 1H), 5.63 (s, 2H), 4.76 (m, 1H), 4.16 (t, 1H), 3.93 (s, 2H), 3.79 (dd, 1H), 3, 43 (m, 2H), 1.83 (s, 3H).

Example 24: Preparation of (R) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5 - ([1,2,4] triazole- 1-yl) methylxazolidin-2-one (Compound 4) *

1. The primary stage

1 g of (R) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5-hydroxymethyl-oxazolidin-2 was dissolved in 14 ml of methylene chloride -one (Compound 10). To the solution was added 0.46 g of methanesulfonyl chloride and 0.75 ml of triethylamine at room temperature and stirred at this same temperature for 30 minutes. Water and brine were added to the reaction mixture for washing, followed by extraction. The organic layer was dehydrated, filtered and concentrated in vacuo to thereby provide (R) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3fluorophenyl) -5-methanesulfonyloxymethyl- oxazolidin-2-one, 1 g. Yield 82%.

2. The secondary stage

The compound prepared in the primary stage was dissolved in 15 ml of dimethylformamide. To the solution was added 300 mg of 1,2,4-triazole and 100 mg of sodium hydride (60%) at room temperature and stirred for 2 days. The reaction mixture was extracted with ethyl acetate and then the organic layer, thus separated, washed with water and brine. The organic layer was dehydrated, filtered and concentrated in vacuo. The residue, prepared by concentrating, was purified by column chromatography to provide the title compound, 400 mg. Yield 43%.

1H NMR (DMSO-d6) δ 8.91 (s, 1H), 8.57 (s, 1H), 8.19 (m, 2H), 7.74 (t, 1H), 7.58 (dd, 1H), 7.42 (dd, 1H), 5.13 (m, 1H), 4.64 (m, 2H), 4.46 (s, 3H), 4.28 (t, 1H), 3, 99 (dd, 1H).

Example 25: Preparation of (R) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5 - ([1,2,3] triazole- 2-yl) methylxazolidin-2-one (Compound 8) and (R) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- ( [1,2,3] triazol-1-yl) methyl-oxazolidin-2-one (Compound 9) *

The same process as in Example 24 was performed, except that, instead of 1,2,4-triazole, 1,2,3-triazole was added to obtain compound 8 and compound 9, and then the compounds were divided by column chromatography.

(Compound 8) 1H NMR (DMSO-d6) δ 8.90 (s, 1H), 8.19 (m, 2H), 7.82 (s, 2H), 7.71 (t, 2H), 7, 59 (dd, 1H), 7.41 (dd, 1H), 5.22 (m, 1H), 4.86 (m, 2H), 4.46 (s, 3H), 4.30 (t, 1H ), 3.98 (dd, 1H).

(Compound 9) 1 H NMR (DMSO-d6) δ 8.90 (s, 1 H), 8.18 (m, 3 H), 7.75 (s, 1 H), 7.72 (t, 1 H), 7, 59 (dd, 1H), 7.42 (dd, 1H), 5.22 (m, 1H), 4.86 (m, 2H), 4.46 (s, 3H), 4.30 (t, 1H ), 3.98 (dd, 1H).

Example 26: Preparation of (R) -3- (4- (2- (2-methyl) - [1,2,3] oxadiazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- ([1,2,3] triazol1-yl) methyl-oxazolidin-2-one (Compound 13) *

The same process as in Example 24 was performed, except for adding 1,2,3-triazole and using compound 16 as a starting material, to obtain the title compound.

1 H NMR (DMSO-d6) δ 8.92 (s, 1 H), 8.20 (s, 2 H), 8.17 (s, 1 H), 7.75 (s, 1 H), 7.73 (t, 1H), 7.61 (dd, 1H), 7.43 (dd, 1H), 5.18 (m, 1H), 4.85 (m, 2H), 4.29 (t, 1H), 3, 96 (dd, 1H), 2.62 (s, 3H)

Example 27: Preparation of (R) -3- (4- (2- [1,2,4] triazol-1-yl) pyridin-5-yl) -3-fluorophenyl) -5 - ([1,2, 3] triazol-1-yl) methylxazolidin-2-one (Compound 14) *

The same process as in Example 24 was performed, except for adding 1,2,3-triazole and using compound 17 as a starting material, to obtain the title compound.

1 H NMR (DMSO-d6) δ 9.40 (s, 1 H), 8.70 (s, 1 H), 8.32 (s, 2 H), 8.25 (d, 1 H), 8.17 (s, 1H), 7.96 (d, 1H), 7.75 (s, 1H), 7.71 (t, 1H), 7.60 (dd, 1H), 7.42 (dd, 1H), 5, 18 (m, 1H), 4.86 (m, 2H), 4.29 (t, 1H), 3.96 (dd, 1H)

Example 28: Preparation of (R) -3- (4- (2- (2-methyltetrazol) -5-yl) pyridin-5-yl) -3-fluorophenyl) -5-fluoromethyl-oxazolidin10 2-one (Compound 18 )

100 mg of Compound 10 was dissolved in 5 ml of methylene chloride. 43 mg of diethylamino sulfur trifluoride (DAST) and 0.078 ml of triethylamine were added to the solution and then stirred for 24 hours. After concentrating, the reaction mixture was purified by column chromatography to obtain the title compound, 75 mg. 75% yield

1 H NMR (DMSO-d6) δ 8.91 (s, 1H), 8.19 (m, 2H), 7.74 (t, 1H), 7.66 (dd, 1H), 7.49 (dd , 1H), 5.06 (m, 1H), 4.89 (m, 2H), 4.46 (s, 3H), 4.23 (t, 1H), 3.95 (dd, 1H)

Example 29: Preparation of (S) -3- (4- (2- (imidazol-1-yl) pyridin-5-yl) -3-fluorophenyl) -5-aminomethyloxazolidin-2-one hydrochloride (Compound 19) *

In 3.4 ml of ethanol and 30.6 ml of pyridine, 2.5 g of (S) -3- (4- (2- (imidazol-1-yl) pyridin-5-yl) -3-fluorophenyl were dissolved )-2

20 oxo-5-oxazolidinylmethyl-acetamide. To the solution was added 2.36 g of hydroxylamine at room temperature and stirred for 10 hours at the temperature of 100 ° C. The reaction mixture was extracted with ethyl acetate and the organic layer, thus separated, washed with water and brine. The organic layer was dehydrated, filtered and concentrated in vacuo. The residue, obtained by concentrating, was purified by column chromatography and then dissolved in tetrahydrofuran solution, saturated hydrochloric acid and stirred for 10 minutes. The solid, prepared by the reaction

25 above, was recrystallized to provide the title compound, 1 g.

Example 30: Preparation of (S) -3- (4- (4- (4,5-dimethyloxazol-2-yl) phenyl) -3-fluorophenyl) -2-oxo-5-oxazolidinylmethylacetamide (Compound 11) *

The same process as in Example 1 was performed, except for adding 4- (4,5-dimethyloxazol-2-yl) -bromobenzene and using (S) -3- (4-trimethylstannyl-3-fluorophenyl) -2-oxo -5-oxazolidinylmethyl-acetamide as a starting material to obtain the title compound.

1H NMR (DMSO-d6) δ 8.24 (m, 1H), 7.96 (m, 2H), 7.62 (m, 4H), 7.45 (dd, 1H), 4.78 (m, 1H), 4.16 (t, 1H), 3.79 (dd, 1H), 3.41 (m, 2H), 2.32 (s, 3H), 2.10 (s, 3H), 1, 83 (s, 3H).

Example 31: Preparation of (S) -3- (4- (2- (4,5-dimethyloxazol-2-yl) pyridin-5-yl) -3-fluorophenyl) -2-oxo-5oxazolidinylmethyl-acetamide (Compound 15 ) *

The same process as in Example 1 was performed, except for adding 4- (4,5-dimethyloxazol-2-yl) -5-bromopyridine and using (S) -3- (4-trimethylstannyl-3-fluorophenyl) - 2-oxo-5-oxazolidinylmethyl-acetamide as a starting material to obtain the title compound.

1H NMR (DMSO-d6) δ 8.81 (s, 1H), 8.24 (t, 1H), 8.07 (m, 2H), 7.77 (t, 1H), 7.62 (dd, 1H), 7.45 (dd, 1H), 4.78 (m, 1H), 4.18 (t, 1H), 3.79 (dd, 1H), 3.42 (m, 2H), 2, 35 (s, 3H), 2.12 (s, 3H), 1.84 (s, 3H).

Example 32: Preparation of (S) -3- (4- (2 - ([1,2,3] triazol-2-yl) pyridin-5-yl) -3-fluorophenyl) -2-oxo-5-oxazolidinylmethylacetamide (Compound 25) *

The same process was performed as in Example 1, except for adding 2 - ([1,2,3] triazol-2-yl) -5-bromopyridine and using (S) -3- (4-trimethylstannyl-3-fluorophenyl) ) -2-oxo-5-oxazolidinylmethyl-acetamide as a starting material to obtain the title compound.

1H NMR (DMSO-d6) δ 8.74 (s, 1H), 8.24 (m, 2H), 8.19 (s, 2H), 8.11 (d, 1H), 7.72 (t, 1H), 7.64 (dd, 1H), 7.45 (dd, 1H), 4.79 (m, 1H), 4.18 (t, 1H), 3.79 (dd, 1H), 3, 43 (m, 2H), 1.84 (s, 3H).

Example 33: Preparation of (S) -3- (4- (4- (4 (S) -hydroxymethyl-4,5-dihydroxazol-2-yl) phenyl) -3-fluorophenyl) -2-oxooxazolidinylmethyl-acetamide (Compound 26) *

The same process was performed as in Example 1, except for adding 4- (4 (S) -hydroxymethyl-4,5-dihydroxazol-2-yl) bromobenzene and use (S) -3- (4-trimethylstannil-3- fluorophenyl) -2-oxo-5-oxazolidinylmethyl-acetamide as a starting material to obtain the title compound.

1H NMR (DMSO-d6) δ 8.23 (t, 1H), 7.91 (d, 2H), 7.62 (m, 4H), 7.42 (dd, 1H), 4.82 (t, 1H), 4.78 (m, 1H), 4.41 (t, 1H), 4.28 (m, 2H), 4.16 (t, 1H), 3.79 (dd, 1H), 3, 61 (m, 1H), 3.48 (m, 1H), 3.43 (m, 2H), 1.84 (s, 3H).

Example 34: Preparation of (S) -3- (4- (4- (4-cyanomethyl-thiazol-2-yl) phenyl) -3-fluorophenyl) -2-oxo-5-oxazolidinemethylacetamide (Compound 31) *

The same process was performed as in Example 1, except for adding 4- (4-cyanomethyl-thiazol-2-yl) -bromobenzene and using (S) -3- (4-trimethylstannyl-3-fluorophenyl) -2-oxo -5-oxazolidinylmethyl-acetamide as a starting material to obtain the title compound.

1H NMR (DMSO-d6) δ 8.25 (t, 1H), 8.00 (d, 2H), 7.67 (m, 4H), 7.44 (dd, 1H), 4.79 (m, 1H), 4.23 (s, 2H), 4.14 (t, 1H), 3.79 (dd, 1H), 3.43 (m, 2H), 1.83 (s, 3H).

Example 35: Preparation of (R) -3- (4- (4- (4-hydroxymethyl-thiazol-2-yl) phenyl) -3-fluorophenyl) -5 - ([1,2,3] triazol-1- il) -methyloxazolidin-2-one (Compound 36) *

The same process was performed as in Example 1, except for adding 4- (4-hydroxymethyl-thiazol-2-yl) -bromobenzene and using (R) -3- (4-trimethylstannyl-3-fluorophenyl) -5- [ 1,2,3] triazol-1-yl-oxazolidin-2-one as a starting material to obtain the title compound.

1H NMR (DMSO-d6) δ 8.16 (s, 1H), 8.00 (d, 2H), 7.75 (s, 1H), 7.64 (dd, 2H), 7.62 (t, 1H), 7.52 (dd, 1H), 7.48 (s, 1H), 7.36 (dd, 1H), 5.40 (t, 1H), 5.18 (m, 1H), 4, 85 (d, 2H), 4.62 (d, 2H), 4.28 (t, 1H), 3.95 (dd, 1H)

Example 36: Preparation of (R) -3- (4- (4- (4-Glyloxymethyl-thiazol-2-yl) phenyl) -3-fluorophenyl) -5 - ([1,2,3] triazol-1il) methyl oxazolidin-2-one-trifluoroacetic acid (Compound 37) *

The same process as in Example 10 was performed, except for using (R) -3- (4- (4- (4-hydroxymethyl-thiazol-2-yl) phenyl) -3fluorophenyl-5- [1,2,3 ] triazol-1-ylmethyl-oxazolidin-2-one as a starting material to obtain the title compound.

1H NMR (DMSO-d6) δ 8.29 (s, 3H), 8.17 (s, 1H), 8.00 (d, 2H), 7.85 (s, 1H), 7.75 (s, 1H), 7.69 (dd, 2H), 7.67 (t, 1H), 7.55 (dd, 1H), 7.43 (dd, 1H), 5.36 (s, 2H), 5, 19 (m, 1H), 4.86 (d, 2H), 4.28 (t, 1H)

Example 37: Preparation of (R) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5-methoxymethyl-oxazolidin-2-one (Compound 33)

In 10 ml of methanol, 400 mg of (R) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5methanesulfonyloxymethyl-oxazolidin-2-one was dissolved prepared in the secondary stage of Example 24. To the solution was added 90 mg of sodium methoxide at room temperature and then stirred for a day at room temperature. The solution was extracted with ethyl acetate and the organic layer, thus separated, washed with water and brine. The organic layer was dehydrated, filtered, concentrated in vacuo and purified by column chromatography to provide the title compound, 200 mg. Yield 58%.

1 H NMR (DMSO-d6) δ 8.90 (s, 1 H), 8.29 (d, 1 H), 8.04 (d, 1 H), 7.61 (dd, 1 H), 7.58 (t, 1H), 7.38 (dd, 1H), 4.80 (m, 1H), 40 4.45 (s, 3H), 4.08 (t, 1H), 3.96 (dd, 1H), 3 , 67 (m, 2H), 3.43 (s, 3H).

Example 38: Preparation of (R) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- (N, N-dimethylaminomethyl) oxazolidin-2-one (Compound 40) *

100 mg of (R) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5methanesulfonyloxymethyl-oxazolidin-2-one was dissolved in 5 ml of dimethylformamide prepared in the secondary step of Example 24. To the solution was added 30 mg of dimethylamine hydrochloride at room temperature. The solution was stirred for 30 hours at the temperature of 60 ° C. And then the solution was extracted with ethyl acetate and the organic layer, thus separated, washed with water and brine. The residue, prepared by dehydrating, filtering and concentrating the organic layer, was purified by column chromatography to provide the title compound, 70 mg. Yield 76%.

1H NMR (DMSO-d6) δ 8.91 (s, 1H), 8.19 (m, 2H), 7.76 (t, 1H), 7.65 (dd, 1H), 7.49 (dd, 1H), 4.98 (m, 1H), 4.63 (s, 3H), 4.27 (m, 3H), 3.94 (dd, 1H), 2.79 (s, 3H), 2, 74 (s, 3H)

Example 39: Preparation of (S) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5-N-methylaminomethyloxazolidin-2-one (Compound 41 ) *

200 mg of (R) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5methanesulfonyloxymethyl-oxazolidin-2-one was dissolved in 7 ml of dimethylformamide , prepared in the primary step of Example 24. To the solution were added 100 mg of methylamine hydrochloride and 240 mg of potassium carbonate at room temperature. The solution was stirred for 30 hours at the temperature of 80 ° C. To the solution was added ethyl acetate and then the organic layer, thus separated, was washed with water and brine. The residue, prepared by dehydrating, filtering and concentrating the organic layer, was purified by column chromatography to provide the title compound, 80 mg. Yield 45%.

1 H NMR (DMSO-d6) δ 8.91 (s, 1 H), 8.18 (m, 2 H), 7.73 (t, 1 H), 7.66 (dd, 1 H), 7.47 (dd, 1H), 7.17 (m, 1H), 4.94 (m, 1H), 4.46 (s, 3H), 4.25 (m, 3H), 3.85 (dd, 1H), 2, 49 (d, 3H)

Example 40: Preparation of (R) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- (L-alanyloxy) methylxazolidin-2-one -trifluoroacetic acid (Compound 42)

The same process as in Example 10 was carried out to provide the title compound using BOC-Lalanine instead of BOC-glycine.

1 H NMR (DMSO-d6) δ 8.91 (s, 1 H), 8.42 (s, 3 H), 8.20 (m, 2 H), 7.75 (t, 1 H), 7.67 (dd, 1H), 7.48 (dd, 1H), 5.05 (m, 1H), 4.61 (dd, 1H), 4.46 (s, 3H), 4.41 (dd, 1H), 4, 26 (t, 1H), 4.18 (m, 1H), 3.96 (dd, 1H), 1.36 (d, 3H),

Example 41: Preparation of (R) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- (Lvalyloxy) methyl-oxazolidin-2 hydrochloride -one (Compound 43)

500 mg of Compound 20, prepared in Example 11, was dissolved in water. The solution was controlled to pH 5 with the addition of aqueous sodium bicarbonate solution. The aqueous layer was extracted with ethyl acetate and then to the organic layer was slowly added solution in ether saturated with hydrochloric acid. The solid prepared by the above method was filtered and concentrated in vacuo to provide the title compound, 200 mg. Yield 46%.

1 H NMR (DMSO-d6) δ 8.92 (s, 1 H), 8.54 (wide s, 3 H), 8.20 (m, 2 H), 7.76 (t, 1 H), 7.65 (dd , 1H), 7.49 (dd, 1H), 5.04 (m, 1H), 4.58 (dd, 1H), 4.46 (s, 3H), 4.41 (dd, 1H), 4 , 26 (t, 1H), 3.95 (m, 2H), 2.17 (m, 1H), 0.97 (d, 3H), 0.94 (d, 3H).

Example 42: Preparation of (R) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- (Lalanyloxy) methyl-oxazolidin-2 hydrochloride -one (Compound 44)

With the exception of using compound 42, the same process as in Example 41 was performed to prepare the title compound.

1 H NMR (DMSO-d6) δ 8.92 (s, 1 H), 8.52 (wide s, 3 H), 8.20 (m, 2 H), 7.75 (t, 1 H), 7.66 (dd , 1H), 7.49 (dd, 1H), 5.05 (m, 1H), 4.60 (dd, 1H), 4.46 (s, 3H), 4.41 (dd, 1H), 4 , 26 (t, 1H), 4.18 (m, 1H), 4.00 (dd, 1H), 1.37 (d, 3H),

Example 43: Preparation of (R) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5-glycyloxymethyl-oxazolidin-2-one hydrochloride (Compound 45 )

With the exception of using compound 12, the same process as in Example 41 was performed to prepare the title compound.

1 H NMR (DMSO-d6) δ 8.91 (s, 1 H), 8.48 (wide s, 3 H), 8.18 (m, 2 H), 7.75 (t, 1 H), 7.65 (dd , 1H), 7.49 (dd, 1H), 5.03 (m, 1H), 4.48 (m, 2H), 4.46 (s, 3H), 4.24 (t, 1H), 3 , 99 (dd, 1H), 3.86 (m, 2H)

Example 44: Preparation of (S) -3- (4- (4- (4-hydroxymethylthiazol-2-yl) phenyl) -3-fluorophenyl) -2-oxo-5-oxazolidinylmethylacetamide (Compound 28) *

With the exception of using (S) -3- (4-trimethylstannyl-3-fluorophenyl) -2-oxo-5-oxazolidinylmethyl-acetamide as starting material and 4- (4-hydroxymethylthiazol-2-yl) -bromobenzene was performed the same process as in Example 1, to prepare the title compound.

1H NMR (DMSO-d6) δ 8.24 (t, 1H), 7.98 (d, 2H), 7.65 (m, 2H), 7.59 (m, 2H), 7.43 (s, 1H), 7.41 (dd, 1H), 5.40 (t, 1H), 4.79 (m, 1H), 4.63 (d, 2H), 4.16 (t, 1H), 3, 79 (dd, 1H), 3.43 (m, 2H), 1.84 (s, 3H).

Example 45: (R) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- (L-prolynyloxy) methyl-oxazolidin-2-one-acid trifluoroacetic (Compound 46)

With the exception of using BOC-L-proline instead of BOC-glycine, the same process as in Example 10 was performed to prepare the title compound.

1H NMR (DMSO-d6) δ 9.25 (broad s, 2H), 8.91 (s, 1H), 8.20 (m, 2H), 7.76 (t, 1H), 7.65 (dd , 1H), 7.48 (dd, 1H), 5.05 (m, 1H), 4.57 (dd, 1H), 4.45 (s, 3H), 4.41 (dd, 1H), 4 , 26 (t, 1H), 3.96 (dd, 1H), 3.23 (m, 2H), 2.21 (m, 1H), 1.92 (m, 3H),

Example 46: Preparation of hydrochloride (R) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- (Lprolinyloxy) methyl-oxazolidin-2- one (Compound 47)

With the exception of using compound 46, the same process as in Example 41 was performed to prepare the title compound.

1H NMR (DMSO-d6) δ 9.11 (broad s, 2H), 8.91 (s, 1H), 8.20 (m, 2H), 7.76 (t, 1H), 7.65 (dd , 1H), 7.49 (dd, 1H), 5.05 (m, 1H), 4.55 (dd, 1H), 4.46 (s, 3H), 4.41 (dd, 1H), 4 , 25 (t, 1H), 4.01 (dd, 1H), 3.36 (m, 2H), 2.07 (m, 1H), 1.89 (m, 3H)

Example 47: Preparation of hydrochloride (R) -3- (4- (2- (2-methyl- [1,3,4] oxadiazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5glyloxymethyl- oxazolidin-2-one (Compound 48) *

With the exception of using compound 27, the same process as in Example 41 was performed to prepare the title compound.

1 H NMR (DMSO-d6) δ 8.92 (s, 1 H), 8.48 (s, 3 H), 8.21 (s, 2 H), 7.76 (t, 1 H), 7.66 (dd, 1H), 7.48 (dd, 1H), 5.04 (m, 1H), 4.47 (m, 2H), 4.23 (t, 1H), 3.94 (m, 1H), 3, 84 (d, 2H), 2.62 (s, 3H)

Example 48: Preparation of (R) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- (β-alanyloxy) methylxazolidin-2-one -trifluoroacetic acid (Compound 49)

With the exception of using BOC-β-alanine instead of BOC-glycine, the same process as in Example 10 was performed to prepare the title compound.

1 H NMR (DMSO-d6) δ 8.91 (s, 1 H), 8.20 (m, 2 H), 7.75 (t, 1 H), 7.73 (wide s, 3 H), 7.68 (dd , 1H), 7.48 (dd, 1H), 5.02 (m, 1H), 4.46 (s, 3H), 4.36 (m, 2H), 4.26 (t, 1H), 3 , 93 (dd, 1H), 3.02 (m, 2H), 2.70 (t, 2H)

Example 49: Preparation of (R) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- (β-alanyloxy) methyl-oxazolidin-2 hydrochloride -one (Compound 50)

With the exception of using Compound 49, the same process as in Example 41 was performed to prepare the title compound.

1H NMR (DMSO-d6) δ 8.91 (s, 1H), 8.22 (m, 2H), 8.11 (wide s, 3H), 7.76 (t, 1H), 7.65 (dd , 1H), 7.48 (dd, 1H), 5.02 (m, 1H), 4.46 (s, 3H), 4.36 (m, 2H), 4.23 (t, 1H), 3 , 95 (m, 1H), 3.00 (m, 2H), 2.74 (t, 2H)

Example 50: Preparation of (R) -3- (4- (2- (2-methyl- [1,3,4] oxadiazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- ( Lalanyloxy) methyl-oxazolidin-2-one-trifluoroacetic acid (Compound 51) *

With the exception of using Compound 16 and BOC-L-alanine, the same process as in Example 10 was performed to prepare the title compound.

1H NMR (DMSO-d6) δ 8.93 (s, 1H), 8.39 (wide s, 3H), 8.21 (s, 2H), 7.76 (t, 1H), 7.68 (dd , 1H), 7.49 (dd, 1H), 5.04 (m, 1H), 4.61 (dd, 1H), 4.40 (dd, 1H), 4.28 (t, 1H), 4 , 18 (dd, 1H), 3.95 (dd, 1H), 2.62 (s, 3H), 1.36 (d, 3H)

Example 51: Preparation of (R) -3- (4- (2- (2-methyl- [1,3,4] oxadiazol-5-yl) pyridin-5-yl) -3-fluorophenyl) 5- hydrochloride (L-Alanyloxy) methyl oxazolidin-2-one (Compound 52) *

With the exception of using Compound 51, the same process as in Example 41 was performed to prepare the title compound.

1 H NMR (DMSO-d6) δ 8.93 (s, 1 H), 8.61 (wide s, 3 H), 8.21 (s, 2 H), 7.76 (t, 1 H), 7.65 (dd , 1H), 7.49 (dd, 1H), 5.05 (m, 1H), 4.58 (dd, 1H), 4.39 (dd, 1H), 4.25 (t, 1H), 4 , 12 (m, 1H), 4.00 (dd, 1H), 2.62 (s, 3H), 1.36 (d, 3H)

Example 52: Preparation of (R) -3- (4- (2- (2-methyl- [1,3,4] oxadiazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- ( Lvalyloxy) methyl-oxazolidin-2-one-trifluoroacetic acid (Compound 53) *

With the exception of using Compound 16 and BOC-L-valine, the same process as in Example 10 was performed to prepare the title compound.

1 H NMR (DMSO-d6) δ 8.93 (s, 1 H), 8.40 (wide s, 3 H), 8.21 (s, 2 H), 7.75 (t, 1 H), 7.68 (dd , 1H), 7.48 (dd, 1H), 5.04 (m, 1H), 4.62 (dd, 1H), 4.40 (dd, 1H), 4.26 (t, 1H), 3 , 99 (d, 1H), 3.92 (dd, 1H), 2.62 (s, 3H), 2.12 (m, 1H), 0.97 (d, 3H), 0.94 (d, 3H).

Example 53: Preparation of (R) -3- (4- (2- (2-methyl- [1,3,4] oxadiazol-5-yl) pyridin-5-yl) -3-fluorophenyl) 5- hydrochloride (L-Valyloxy) methyl-oxazolidin-2-one (Compound 54) *

With the exception of using Compound 53, the same process was performed as in Example 41 to prepare the title compound.

1 H NMR (DMSO-d6) δ 8.93 (s, 1 H), 8.60 (wide s, 3 H), 8.21 (s, 2 H), 7.75 (t, 1 H), 7.67 (dd , 1H), 7.49 (dd, 1H), 5.04 (m, 1H), 4.58 (dd, 1H), 4.42 (dd, 1H), 4.26 (t, 1H), 3 , 92 (m, 1H), 2.62 (s, 3H), 2.12 (m, 1H), 0.97 (d, 3H), 0.94 (d, 3H).

Example 54: Preparation of (R) -3- (4- (2- (2-methyl- [1,3,4] oxadiazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- ( Lprolinyloxy) methyl-oxazolidin-2-one-trifluoroacetic acid (Compound 55) *

With the exception of using Compound 16 and BOC-L-proline, the same process as in Example 10 was performed to prepare the title compound.

1H NMR (DMSO-d6) δ 9.20 (broad s, 2H), 8.93 (s, 1H), 8.21 (s, 2H), 7.77 (t, 1H), 7.66 (dd , 1H), 7.50 (dd, 1H), 5.04 (m, 1H), 4.59 (dd, 1H), 4.43 (m, 2H), 4.26 (t, 1H), 3 , 96 (dd, 1H), 3.21 (m, 2H), 2.62 (s, 3H), 2.21 (m, 1H), 1.95 (m, 1H), 1.89 (m, 2H).

Example 55: Preparation of (R) -3- (4- (2- (2-methyl- [1,3,4] oxadiazol-5-yl) pyridin-5-yl) -3-fluorophenyl) 5- hydrochloride (L-prolynyloxy) methyl-oxazolidin-2-one (Compound 56) *

With the exception of using Compound 55, the same process was performed as in Example 41 to prepare the title compound.

1H NMR (DMSO-d6) δ 9.18 (broad s, 2H), 8.93 (s, 1H), 8.21 (s, 2H), 7.76 (t, 1H), 7.65 (dd , 1H), 7.49 (dd, 1H), 5.05 (m, 1H), 4.57 (dd, 1H), 4.43 (m, 2H), 4.26 (t, 1H), 4 , 00 (dd, 1H), 3.21 (m, 2H), 2.62 (s, 3H), 2.21 (m, 1H), 1.95 (m, 1H), 1.89 (m, 2H)

Example 56: Preparation of (R) -3- (4- (2- (2-methyl- [1,3,4] oxadiazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- ( β-Alanyloxy) methyl-oxazolidin-2-one-trifluoroacetic acid (Compound 57) *

With the exception of using Compound 16 and BOC-β-alanine, the same process was performed as in Example 10 to prepare the title compound.

1H NMR (DMSO-d6) δ 8.92 (s, 1H), 8.21 (s, 2H), 7.88 (wide s, 3H), 7.76 (t, 1H), 7.68 (dd , 1H), 7.49 (dd, 1H), 5.02 (m, 1H), 4.36 (m, 2H), 4.25 (t, 1H), 3.94 (dd, 1H), 3 , 03 (m, 2H), 2.70 (t, 2H), 2.62 (s, 3H)

Example 57: Preparation of (R) -3- (4- (2- (2-methyl- [1,3,4] oxadiazol-5-yl) pyridin-5-yl) -3-fluorophenyl) 5- hydrochloride (β-alanyloxy) methyl-oxazolidin-2-one (Compound 58) *

With the exception of using Compound 57, the same process was performed as in Example 41 to prepare the title compound.

1 H NMR (DMSO-d6) δ 8.92 (s, 1 H), 8.21 (s, 2 H), 8.08 (wide s, 3 H), 7.76 (t, 1 H), 7.68 (dd , 1H), 7.49 (dd, 1H), 5.02 (m, 1H), 4.36 (m, 2H), 4.25 (t, 1H), 3.96 (dd, 1H), 3 , 00 (m, 2H), 2.70 (t, 2H), 2.62 (s, 3H)

Example 58: Preparation of mono - [(R) - [3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -2-oxo5-oxazolidin] phosphate] methyl] (Compound 72) and disodium phosphate of (R) - [3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3fluorophenyl) -2-oxo-5-oxazolidin] methyl (Compound 59)

5 1. The primary stage

In 10 ml of a mixing solvent (tetrahydrofuran: methylene chloride = 1: 1) 1 g of Compound 10 was dissolved. 0.6 g of tetrazole and 2.3 g of di-tetrabutyl diisopropylphosphamamide were added to the solution and stirred for 15 hours at room temperature. The reaction mixture was cooled to -78 ° C, 0.7 g of metachloroperbenzoic acid was added and stirred for 2 hours. After cooling to -78 ° C, the reaction mixture was added

10 metachloroperbenzoic acid (0.7 g). When the reaction mixture was stirred for 2 hours, the temperature of the reaction mixture rose to room temperature. Then, ethyl acetate was added to the reaction mixture. The organic layer, thus separated, was washed with sodium bisulfate, sodium bicarbonate and brine, dehydrated, filtered and concentrated in vacuo, followed by purification with column chromatography to thereby provide ditetrabutyl acid ester (R) - [3- (4- (2- (2-Methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -2-oxo-5-oxazolidinyl] methyl (0.71 g,

15 71%).

1 H NMR (DMSO-d6) δ 8.90 (s, 1 H), 8.18 (m, 2 H), 7.74 (t, 1 H), 7.68 (dd, 1 H), 7.49 (dd, 1H), 4.98 (m, 1H), 4.46 (s, 3H), 4.23 (t, 1H), 4.18 (m, 1H), 4.09 (m, 1H), 3, 89 (dd, 1H), 1.39 (s, 9H), 1.38 (s, 9H)

The crystal prepared by the above method was dissolved in a mixture of methanol and chloroform. And then to the solution, 3.4 ml of sodium methoxide (0.3 M solution in methanol) was added at room temperature and

20 stirred for 10 hours. The reaction mixture was concentrated to prepare the residue. The residue was crystallized and filtered to thereby obtain the title compound (Compound 59), 300 mg.

1H NMR (D2O) δ 8.27 (s, 1H), 7.56 (dd, 2H), 7.06 (m, 2H), 6.90 (m, 1H), 4.79 (m, 1H) , 4.63 (s, 3H), 3.90 (m, 4H)

2. The secondary stage

The compound (0.7 g) was dissolved in the primary stage in 30 ml of methylene chloride. To the solution were added 15

25 ml of trifluoroacetic acid and then stirred for 1 hour at room temperature. The reaction mixture was concentrated in vacuo to prepare the residue. The residue was crystallized with ethanol and ethyl ether to obtain mono - [(R) - [3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) phosphate) -2-oxo-5-oxazolidinyl] methyl] (Compound 72), 400 mg.

1 H NMR (DMSO-d6) δ 8.92 (s, 1 H), 8.20 (m, 2 H), 7.74 (t, 1 H), 7.66 (dd, 1 H), 7.50 (dd, 1H), 4.95 (m, 1H), 4.46 (s,

3H), 4.21 (t, 1H), 4.05 (m, 2H), 3.91 (dd, 1H)

Example 59: Preparation of disodium phosphate of (R) - [3- (4- (2- (2-methyl- [1,3,4] oxadiazol-5-yl) pyridin-5-yl) -3-fluorophenyl) - 2-oxo-5-oxazolidinyl] methyl (Compound 60) *

Using Compound 16, the title compound was prepared in a manner similar to that of Example 58.

1H NMR (D2O) δ 8.33 (s, 1H), 7.65 (dd, 2H), 7.17 (m, 2H), 6.90 (m, 1H), 4.79 (m, 1H) , 4.63 (s, 3H), 3.94 (m, 4H), 3.78 (m, 3H)

Example 60: Preparation of (R) -3- (4- (2- (1-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5-hydroxymethyloxazolidin-2-one (Compound 61)

Using 2- (1-methyltetrazol-5-yl) -5-bromopyridine, the title compound was prepared in a manner similar to that of Example 1.

1H NMR (DMSO-d6) δ 8.98 (s, 1H), 8.30 (m, 2H), 7.75 (m, 2H), 7.53 (dd, 1H), 5.25 (t, 1H), 4.76 (m, 1H), 4.44 (s, 3H), 40 4.14 (t, 1H), 3.89 (dd, 1H), 3.69 (m, 1H), 3 , 58 (m, 1 H)

Example 61: Preparation of (R) -3- (4- (2- (1-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5-glycyloxymethyloxazolidin-2-one-trifluoroacetic acid (Compound 62)

Using 2- (1-methyltetrazol-5-yl) -5-bromopyridine, the title compound was prepared in a manner similar to that of Example 10.

1 H NMR (DMSO-d6) δ 8.95 (s, 1 H), 8.20 (s, 3 H), 8.19 (m, 2 H), 7.80 (t, 1 H), 7.69 (dd, 1H), 7.49 (dd, 1H), 5.00 (m, 1H), 4.46 (m, 2H), 4.45 (s, 3H), 4.24 (t, 1H), 3, 92 (dd, 1H), 3.90 (s, 2H)

Example 62: Preparation of (R) -3- (4- (2- (1-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5-glycyloxymethyl-oxazolidin-2-one hydrochloride (Compound 63)

Using 2- (1-methyltetrazol-5-yl) -5-bromopyridine, the title compound was prepared in a manner similar to that of Example 43.

1 H NMR (DMSO-d6) δ 8.95 (s, 1 H), 8.50 (wide s, 3 H), 8.21 (m, 2 H), 7.80 (t, 1 H), 7.65 (dd , 1H), 7.49 (dd, 1H), 5.03 (m, 1H), 4.48 (m, 2H), 4.43 (s, 3H), 4.24 (t, 1H), 3 , 99 (dd, 1H), 3.86 (m, 2H)

Example 63: Preparation of (R) -3- (4- (2- (1-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- (L-alanyloxy) methylxazolidin-2-one -trifluoroacetic acid (Compound 64)

Using 2- (1-methyltetrazol-5-yl) -5-bromopyridine, the title compound was prepared in a manner similar to that of Example 40.

1 H NMR (DMSO-d6) δ 8.95 (s, 1 H), 8.43 (s, 3 H), 8.25 (m, 2 H), 7.77 (t, 1 H), 7.68 (dd, 1H), 7.48 (dd, 1H), 5.05 (m, 1H), 4.63 (dd, 1H), 4.44 (s, 3H), 4.42 (dd, 1H), 4, 24 (t, 1H), 4.18 (m, 1H), 3.98 (dd, 1H), 1.36 (d, 3H)

Example 64: Preparation of (R) -3- (4- (2- (1-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- (Lalanyloxy) methyl-oxazolidin-2 hydrochloride -one (Compound 65)

Using 2- (1-methyltetrazol-5-yl) -5-bromopyridine, the title compound was prepared in a manner similar to that of Example 42.

1 H NMR (DMSO-d6) δ 8.95 (s, 1 H), 8.53 (wide s, 3 H), 8.24 (m, 2 H), 7.77 (t, 1 H), 7.67 (dd , 1H), 7.49 (dd, 1H), 5.05 (m, 1H), 4.60 (dd, 1H), 4.43 (s, 3H), 4.42 (dd, 1H), 4 , 26 (t, 1H), 4.20 (m, 1H), 4.00 (dd, 1H), 1.37 (d, 3H)

Example 65: Preparation of (R) -3- (4- (2- (1-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- (L-valyloxy) methylxazolidin-2-one -trifluoroacetic acid (Compound 66)

Using 2- (1-methyltetrazol-5-yl) -5-bromopyridine, the title compound was prepared in a manner similar to that of Example 11.

1 H NMR (DMSO-d6) δ 8.95 (s, 1 H), 8.42 (s, 3 H), 8.25 (m, 2 H), 7.79 (t, 1 H), 7.70 (dd, 1H), 7.48 (dd, 1H), 5.05 (m, 1H), 4.64 (dd, 1H), 4.44 (s, 3H), 4.43 (dd, 1H), 4, 30 (t, 1H), 4.01 (d, 1H), 3.93 (dd, 1H), 2.14 (m, 2H), 0.98 (d, 3H), 0.95 (d, 3H )

Example 66: Preparation of (R) -3- (4- (2- (1-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- (Lvalyloxy) methyl-oxazolidin-2 hydrochloride -one (Compound 67)

Using 2- (1-methyltetrazol-5-yl) -5-bromopyridine, the title compound was prepared in a manner similar to that of Example 41.

1H NMR (DMSO-d6) δ 8.94 (s, 1H), 8.57 (wide s, 3H), 8.22 (m, 2H), 7.79 (t, 1H), 7.67 (dd , 1H), 7.49 (dd, 1H), 5.04 (m, 1H), 4.59 (dd, 1H), 4.43 (s, 3H), 4.41 (dd, 1H), 4 , 27 (t, 1H), 3.99 (m, 2H), 2.17 (m, 1H), 0.97 (d, 3H), 0.94 (d, 3H)

Example 67: Preparation of (R) -3- (4- (2- (1-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- (β-alanyloxy) methylxazolidin-2-one -trifluoroacetic acid (Compound 68)

Using 2- (1-methyltetrazol-5-yl) -5-bromopyridine, the title compound was prepared in a manner similar to that of Example 48.

1 H NMR (DMSO-d6) δ 8.94 (s, 1 H), 8.24 (m, 2 H), 7.77 (t, 1 H), 7.73 (wide s, 3 H), 7.70 (dd , 1H), 7.49 (dd, 1H), 5.02 (m, 1H), 4.44 (s, 3H), 4.36 (m, 2H), 4.27 (t, 1H), 3 , 93 (dd, 1H), 3.05 (m, 2H), 2.70 (t, 2H)

Example 68: Preparation of (R) -3- (4- (2- (1-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- (β-alanyloxy) methyl-oxazolidin-2 hydrochloride -one (Compound 69)

Using 2- (1-methyltetrazol-5-yl) -5-bromopyridine, the title compound was prepared in a manner similar to that of Example 49.

1 H NMR (DMSO-d6) δ 8.96 (s, 1 H), 8.25 (m, 2 H), 8.13 (wide s, 3 H), 7.79 (t, 1 H), 7.66 (dd , 1H), 7.48 (dd, 1H), 5.02 (m, 1H), 4.43 (s, 3H), 4.36 (m, 2H), 4.25 (t, 1H), 3 , 97 (m, 1H), 3.01 (m, 2H), 2.74 (t, 2H)

Example 69: Preparation of mono - [(R) - [3- (4- (2- (1-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -2-oxo5-oxazolidin] phosphate] methyl] (Compound 73) and disodium phosphate of (R) - [3- (4- (2- (1-methyltetrazol-5-yl) pyridin-5-yl) -3fluorophenyl) -2-oxo-5-oxazolidin] methyl (Compound 70)

1.-The primary stage

Using compound 61, (R) - [3- (4- (2- (1-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -2oxo-5-oxazolidinyl] methyl acid ditetrabutyl ester -phosphoric was prepared in a manner similar to that of Example 58.

1 H NMR (DMSO-d6) δ 8.94 (s, 1 H), 8.20 (m, 2 H), 7.78 (t, 1 H), 7.68 (dd, 1 H), 7.49 (dd, 1H), 4.98 (m, 1H), 4.44 (s, 3H), 4.21 (t, 1H), 4.18 (m, 1H), 4.10 (m, 1H), 3, 89 (dd, 1H), 1.39 (s, 9H), 1.38 (s, 9H)

2. The secondary stage Using the compound provided in the primary stage, 400 mg of mono phosphate - [(R) - [3- (4- (2- (1

methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -2-oxo-5-oxazolidinyl] methyl] (Compound 73) was prepared in a manner similar to that of Example 58. 1 H NMR (DMSO-d6) δ 8.95 (s, 1 H), 8.23 (m, 2 H), 7.76 (t, 1 H), 7.66 (dd, 1 H), 7.50 (dd, 1H), 4.95 (m, 1H), 4.44 (s, 3H),

4.21 (t, 1H), 4.05 (m, 2H), 3.91 (dd, 1H) The title compound (Compound 70) was obtained in a manner similar to that of Example 58. 1 H NMR (D2O ) δ 8.29 (s, 1H), 7.60 (dd, 2H), 7.10 (m, 2H), 6.90 (m, 1H), 4.79 (m, 1H), 4.60 (s, 3H), 3.90 (m, 4H)

Example 70: Preparation of (R) -3- (4- (2- (1-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5 - ([1,2,3] triazole- 1-yl) methylxazolidin-2-one (Compound 71) *

Using Compound 61, the title compound was prepared in a manner similar to that of Example 24.

1 H NMR (DMSO-d6) δ 8.95 (s, 1 H), 8.21 (m, 3 H), 7.77 (s, 1 H), 7.75 (t, 1 H), 7.59 (dd, 1H), 7.42 (dd, 1H), 5.22 (m, 1H), 4.86 (m, 3H), 4.44 (s, 3H), 4.31 (t, 1H), 3, 98 (dd, 1H)

Experimental Example 1: In vitro antibacterial activity assay

To test an antibacterial activity of oxazolidinone derivatives, antibacterial activity, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE), was represented as the minimum inhibitory concentration (MIC50, μg / ml) using a dilution in agar described in the art (Chemotherapy, 29 (1), 76, (1981)). Zyvox from Pharmacia &amp; Upjohn Inc, corresponding to Formula 3, was used as a control. Results are shown in table 2.

[Table 2]

Compound

Minimum Inhibitory Concentration (MIC50, µg / ml)  Compound Minimum Inhibitory Concentration (MIC50, µg / ml)

MRSA

VRE  MRSA VRE

Zyvox

2 2 37 0.5 0.5

one *

one 0.25 38 0.5 one

2 *

0.5 0.125 39 one one

3*

0.25 0.25 40 4 8

4 *

2 2 41 4 8

5 *

0.5 0.25 42 0.5 0.25

6 *

NA NA 43 0.5 0.25

7 *

0.5 0.5 44 0.5 0.25

8 *

16 16 Four. Five 0.5 0.25

9 *

0.25 0.125 46 0.5 0.25

10 *

0.5 0.25 47 0.5 0.25

eleven *

0.5 0.25 48 0.5 one

12 *

0.5 0.25 49 0.5 0.25

13 *

0.25 0.25 fifty 0.5 0.25

14 *

0.25 0.25 51 0.5 one

fifteen *

one one 52 0.5 one

16 *

0.5 one 53 0.5 one

17 *

one one 54 0.5 one

18 *

one 2 55 0.5 one

19 *

32 32 56 0.5 one

twenty

0.5 0.25 57 0.5 one

twenty-one *

one one 58 0.5 one

22 *

one one 59 0.5 0.25

2. 3 *

2 2 60 0.5 one

24 *

0.5 0.5 61 0.5 0.25

25 *

0.25 0.125 62 0.5 0.25

26 *

0.5 0.5 63 0.5 0.25

27 *

0.5 one 64 0.5 0.25

28 *

0.5 0.5 65 0.5 0.25

29 *

0.5 one 66 0.5 0.25

30 *

0.5 0.5 67 0.5 0.25

31 *

0.5 0.5 68 0.5 0.25

32 *

0.5 one 69 0.5 0.25

33 *

2 2 70 0.5 0.25

3. 4 *

one one 71 0.5 0.125

35 *

one one 72 32 32

36 *

0.5 0.5 73 32 32

NA: Not determined MRSA: Methicillin-resistant Staphylococcus aureus VRE: Vancomycin-resistant Enterococci

As illustrated in Table 2, the derivatives of the present invention had sufficient efficacy on the antibacterial activity against Staphylococcus aureus (MRSA) and Enterococci (VRE), despite using a lower concentration of the derivatives than that of Zyvox. Accordingly, the compounds of the present invention

5 can be used as antibiotics.

Experimental Example 2: Solubility Test

To test a solubility of the derivatives of the present invention, an experiment was carried out as indicated below. Derivatives of the present invention were added to 200

μl of distilled water and then the

solution was stirred for 2 minutes. The turbidity of the solution was monitored with the naked eye.

When the derivatives did not dissolve completely, 50 µl of distilled water was added to the solution, and then the turbidity of the solution was analyzed in the above manner to find a point to make the solution transparent.

When 2 mg of the derivatives were first added to distilled water and dissolved completely, so that the solution became transparent, an additional 2 mg of the derivatives was added to the solution and then the

15 state of dissolution. The derivatives of the present invention were added five times and then the solubility of the solution was analyzed. The solubility test was carried out three times repeatedly in the previous method and the results were averaged. The averages are shown in Table 3.

[Table 3] As shown in Table 3, the solubility of compound 42 (> 50 mg / ml) that becomes a prodrug of the derivatives was enhanced compared to that of Zyvox (3 mg / ml) and the Compound 10 (10 μg / ml).

Compound

Solubility  Compound Solubility

Zyvox

3 mg / ml 51 > 50 mg / ml

10

10 mg / ml 52 > 50 mg / ml

12

28 mg / ml 53 30.3 mg / ml

16 *

20 mg / ml 54 2.9 mg / ml

twenty

4.7 mg / ml 55 7.2 mg / ml

27 *

> 50 mg / ml 56 > 50 mg / ml

42

> 50 mg / ml 57 > 50 mg / ml

43

4.2 mg / ml 58 5.5 mg / ml

44

> 50 mg / ml 59 > 50 mg / ml

Four. Five

12 mg / ml 60 > 50 mg / ml

46

<1.63 mg / ml 62 28 mg / ml

47

2 mg / ml 64 > 50 mg / ml

48 *

> 50 mg / ml 66 4.7 mg / ml

49

2.6 mg / ml 68 2.6 mg / ml

fifty

20.4 mg / ml 70 > 50 mg / ml

Therefore, when the derivatives of the present invention were formulated for oral administration, the absorption of the derivatives can be enhanced. When the derivatives were formulated as an injection, various formations of the derivatives can be obtained.

Experimental Example 3: Acute toxicity test by oral administration of the derivatives to mice

To test the acute toxicity of the compounds of the present invention, the following experiment was carried out.

A mixture of 1% hydroxypropyl methylcellulose and 200 mg of one selected from the group consisting of Compounds 10, 12, 16, 17, 20, 22, 24 and 27 was administered to 5 ICR mice (5 week old males, 20 g + 2 g weight). And then lethality was observed for 2 weeks, weight, symptoms, etc. to determine the minimum lethal dose (DLM, mg / kg). As a control, Zyvox from Pharmacia &amp; Upjohn Inc. The results are represented in Table 4.

[Table 4]

Compound

Minimum lethal dose (DLM, mg / kg)

Zyvox

> 1000

10

> 1000

12

> 1000

16 *

> 1000

17 *

> 1000

twenty

> 1000

22 *

> 1000

24 *

> 1000

27 *

> 1000

Observation of survival, weight change, blood tests and toxicity syndrome, etc. demonstrated that the administration of the composition of the present invention has no toxic effects.

The compounds of the present invention have excellent efficacy on antibacterial activity without any toxicity present in accordance with Table 4.

Formulation Example: Preparation of pharmaceutical compositions

1. Preparation in powder form Oxazolidinone derivative 2 g

10 Lactose 1 g The above materials were mixed and then the mixture was placed in a closed container to prepare a powder.

2. Preparation in tablet form Oxazolidionone 500 mg derivative 100 mg corn starch

15 Lactose 100 mg Magnesium stearate 2 mg The above materials were mixed and then the mixture was transformed into tablets by the known method of preparing a tablet.

3. Preparation of capsules

20 Oxazolidionone derivative 500 mg Corn starch 100 mg Lactose 100 mg Magnesium stearate 2 mg

The above materials were mixed and the mixture was filled into gelatin capsules by the known method of preparing a capsule.

4. Preparation of an injection Oxazolidinone derivative 500 mg 5 Citrate buffer maintain a pH of 3.5 Dextrose isotonicity The oxazolidinone derivative, sodium citrate salt, citric acid and dextrose were incorporated into a 20 ml vial, sterilized to the injection and then closed using an aluminum cap. The mixture was dissolved in water

distilled for injection and then diluted in distilled water solution, with an appropriate volume for injection. 10

Claims (10)

1.-An oxazolidinone derivative of formula I or a pharmaceutically acceptable salt thereof: formula (I) wherein R1 and R’1 are independently hydrogen or fluorine; R2 is -OR7, fluorine, alkyl phosphate, monophosphate or a metal phosphate salt; R7 is hydrogen, C1-3alkyl or acylated amino acid, wherein the amino acid is alanine, proline, isoleucine, leucine, phenylalanine, β-alanine or valine; R3 is hydrogen, a C1-4 alkyl group that is unsubstituted or substituted with cyano or - (CH2) m-OR7; and m is 0, 1, 2, 3 or 4. 2. The compound of claim 1, wherein R1 is hydrogen and R’1 is fluorine. 3. The compound of claim 1 or 2, wherein R2 is -OH. 4. The compound of claim 1 or 2, wherein R2 is -OR7 and R7 is the acylated amino acid. 5. The compound of claim 1 or 2, wherein R2 is selected from the group consisting of alkyl phosphate, monophosphate and a metal phosphate salt. 6. The compound of any of claims 1-5, wherein R3 is methyl. 7. The compound of any of claims 1-6, wherein the pharmaceutically acceptable salt is formed with an acid selected from the group consisting of hydrochloric acid, bromic acid, sulfuric acid, phosphoric acid, citric acid, acetic acid, lactic acid, maleic acid, fumaric acid, gluconic acid, methanesulfonic acid, glyconic acid, succinic acid, acid 4 -toluenesulfonic acid, trifluoroacetic acid, galacturonic acid, embionic acid, glutamic acid and aspartic acid. 8. The compound of claim 7, wherein the acid is hydrochloric acid or trifluoroacetic acid. 9. The compound of claim 1, which is selected from the group consisting of Compound 10) (R) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3- fluorophenyl) -5-hydroxymethyl-oxazolidin-2-one; Compound 12) (R) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5-glycyloxymethyl-oxazolidin-2-one trifluoroacetic acid; Compound 18) (R) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5-fluoromethyl-oxazolidin-2-one; Compound 20) (R) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- (L-valyloxy) methyl-oxazolidin-2-one trifluoroacetic acid; Compound 33) (R) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5-methoxymethyl-oxazolidin-2-one; Compound 38) (R) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3,5-difluorophenyl) -5-hydroxymethyl-oxazolidin-2-one; Compound 42) (R) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- (L-alanyloxy) methyl-oxazolidin-2-annacid trifluoroacetic; Compound 43) (R) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- (L-valyloxy) methylxazolidin-2-one hydrochloride ; Compound 44) (R) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- (L-alanyloxy) methylxazolidin-2-one hydrochloride ; Compound 45) (R) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5-glycyloxymethyloxazolidin-2-one hydrochloride; Compound 46) (R) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- (L-prolynyloxy) methyl-oxazolidin-2ona-acid trifluoroacetic; Compound 47) (R) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- (L-prolynyloxy) methylxazolidin-2-one hydrochloride ; Compound 49) (R) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- (β-alanyloxy) methyl-oxazolidin-2-annacid trifluoroacetic; Compound 50) (R) -3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- (β-alanyloxy) methylxazolidin-2-one hydrochloride ; Compound 59) (R) - [3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -2-oxo-5oxazolidinyl] methyl disodium phosphate; Compound 61) (R) - [3- (4- (2- (1-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5-hydroxymethyl-oxazolidin-2-one; Compound 62) (R) - [3- (4- (2- (1-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5-glycyloxymethyl-oxazolidin-2-one-acid trifluoroacetic acid; Compound 63) (R) -3- (4- (2- (1-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5-glycyloxymethyloxazolidin-2-one hydrochloride; Compound 64) (R) -3- (4- (2- (1-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- (L-alanyloxy) methyl-oxazolidin-2-annacid trifluoroacetic; Compound 65) (R) -3- (4- (2- (1-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- (L-alanyloxy) methylxazolidin-2-one hydrochloride ; Compound 66) (R) -3- (4- (2- (1-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- (L-valyloxy) methyl-oxazolidin-2-one-acid trifluoroacetic; Compound 67) (R) -3- (4- (2- (1-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- (L-valyloxy) methylxazolidin-2-one hydrochloride ; Compound 68) (R) -3- (4- (2- (1-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- (β-alanyloxy) methyl-oxazolidin-2-annacid trifluoroacetic; Compound 69) (R) -3- (4- (2- (1-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5- (β-alanyloxy) methylxazolidin-2-one hydrochloride ; Compound 70) disodium phosphate of (R) - [3- (4- (2- (1-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -2-oxo-5oxazolidinyl] methyl; Compound 72) mono - [(R) - [3- (4- (2- (2-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -2-oxo-5oxazolidinyl] methyl] phosphate] ; and Compound 73) mono - [(R) - [3- (4- (2- (1-methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -2-oxo-5oxazolidinyl] methyl phosphate ]. 10. The compound of claim 1 having the formula 11. The compound of claim 1 having the formula 12. The compound of claim 1 which is 13. A pharmaceutical composition comprising the compound of any of claims 1-12. 14. The compound or composition of any of claims 1-13, for use in the treatment of a bacterial infection in a subject. 15. The compound or composition of claim 14, wherein the bacterial infection results from a Gram-positive bacterium. 16. The compound or composition of claim 15, wherein the Gram-positive bacterium is selected from the group consisting of Staphylococcus, Enterococcus, Streptococcus, Bacteroides, Clostridium and Mycobacterium.